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Abstract 
Purpose: At the Wellington Blood and Cancer Centre (WBCC), Volumetric Modulated Arc 
Therapy (VMAT) is used to treat a variety of head and neck (H&N) cancers. Presently, the 
complexity of plans is limited to ensure the accuracy of patient treatment within the range of 
the departmental experience. The complexity limitation is applied through use of a monitor 
unit (MU) constraint during plan optimisation. Plans of higher complexity can be obtained by 
loosening the MU constraint, and setting more stringent optimisation objectives on organs at 
risk (OAR) and target volumes (PTV). This could potentially yield higher quality treatment 
plans but may also degrade the accuracy of the TPS calculation or the plan delivery at the 
treatment machine. The aim of this study is to investigate the level of plan complexity that 
results in accurate treatment plan calculation and delivery, and quantify the corresponding 
gain in plan quality. 
Methods: Five previously treated H&N patients were selected for the study. Each patient’s 
clinical plan was used as the lowest complexity level and labelled C1. Subsequently, an 
approximate pareto-optimal plan (C3) was created that focused equally on sparing spinal 
cord, brain stem and parotid gland while maintaining, or improving on, the previously 
obtained target coverage. Next, a C2 plan was created such that the plan quality was in 
between C1 and C3. Plan quality of each complexity level was assessed in terms of OAR 
sparing and PTV coverage. The average leaf pair opening (LPO), critical leaf pair opening 
(%LPO<1cm) and mean leaf travel were used as plan complexity metrics.  
The calculation and delivery accuracy of each complexity level using Varian TrueBeam 
LINAC/Eclipse TPS was verified using time resolved point dose measurements (TRPD), EBT 
film measurements (Ashland Inc.) and ArcCheck measurements (Sun Nuclear Corp.). A 
comprehensive uncertainty analysis was carried out including a quantification of the 
measurement and delivery reproducibility. 
Results: Increasing plan complexity from C1 to C3 reduced the Spinal Cord D1cc, Brain Stem 
D1 and Parotid Gland Dmean up to 14.7 Gy, 7.1 Gy and 7.8 Gy, respectively. In addition, C3 
plans improved the target coverage compared to C1 plans, with the PTV66 and PTV54 D98 
increasing up to 1.0 Gy and 0.6 Gy, respectively. The verification measurements showed that 
the plan calculation and delivery for all complexity levels was well within clinical acceptance 
levels (Table 1). TRPD showed that VMAT dose delivery itself was repeatable within 0.1% 
(1 S.D.) over 10 consecutive deliveries for both C1 and C3 complexity levels. 
Discussion & Conclusions: This study has shown that increasing the plan complexity can 
provide significant dosimetric advantages for the treatment of H&N cancer. Verification 
measurement results indicated that this did not noticeably degrade the calculation and 
delivery accuracy of VMAT using a Varian TrueBeam LINAC and our Eclipse TPS beam 
model. H&N VMAT at the WBCC can now be developed further with greater confidence in 
the dosimetric accuracy of higher complexity plans. 
Table 1: TRPD, EBT film and ArcCheck results; γ-analysis was performed using a {2%; 2 mm} criterion  
Complexity level Mean point dose 
deviation ± 1 S.D. 
Mean EBT film γ pass-
rate ± 1 S.D. 
Mean ArcCheck 
γ pass-rate ± 1 S.D. 
C1 -0.1% ± 1.0% 95% ± 3% 96% ± 4% 
C2 -0.1% ± 1.2% 95% ± 2% 95% ± 3% 
C3 0.0% ± 1.2% 96% ± 2% 94% ± 5% 
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1. Introduction 
1.1. Head and neck cancer 
Head and neck (H&N) cancer is carcinoma (commonly epithelial squamous-cell 
carcinoma) that affects the oral cavity, nasal cavity, pharynx, larynx, salivary glands 
and paranasal sinuses [1]. Around two thirds of patients present with later stage 
disease that has commonly spread to the regional lymph nodes [2]. The important risk 
factors for H&N cancer have been attributed to cigarette smoking, alcohol 
consumption [3, 4, 5] and exposure to human papilloma virus [6]. The incidence of 
H&N cancer is greatest for those aged over 50 but the incidence for younger adults 
has recently increased [7, 8]. As of 2013, approximately 520 new cases of H&N 
cancer are registered with the ministry of health in New Zealand each year [9]. 
Standard treatment of H&N cancer includes surgery, chemotherapy and radiotherapy. 
Either surgery or radiotherapy is used for treatment of stage I or II disease with the 
intent of curing the disease. Radiotherapy can also be used as a postoperative 
treatment [10].  For locally advanced disease, chemotherapy is often administered 
concurrently with radiotherapy [11]. 
 
Radiotherapy as an effective treatment of H&N cancer requires that the targeted 
volumes are correctly irradiated to a prescribed dose level. The effectiveness of the 
treatment depends on its ability to eliminate the tumour cells where the probability of 
doing this with a certain dose is dictated by the tumour control probability (TCP) [12]. 
However, the safe application of radiotherapy also requires that the organs at risk 
(OAR) are spared from radiation dose levels that may cause damage (i.e. radiation 
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induced toxicities). The probability that a certain dose will damage an OAR to some 
end point is defined by the normal tissue complication probability (NTCP) [13]. For 
example, delivering a mean dose above ~26 Gy to the parotid glands greatly increases 
the NTCP for xerostomia where salivary production by the parotid glands is severely 
reduced [14]. Additionally, delivering a 50 Gy or higher maximum dose to the spinal 
cord can result in myelopathy where at its worst grade results in paralysis, complete 
loss of sensory function and complete incontinence [15]. Radiotherapy is a trade-off 
between increasing TCP by irradiating the targeted volumes with a high dose while 
ensuring low NTCP to avoid radiation toxicities that impact on the patient’s quality of 
life. To do this, radiotherapy treatments are fractionated where the total dose is 
delivered in multiple sessions to spare slow responding tissues (like many OARs) 
more than fast responding tissues (like many tumours) [16]. Additionally, conformal 
treatment delivery techniques that selectively irradiate the target volumes while 
sparing OARs have been pursued. 
 
Radiotherapy of the H&N is difficult because the targeted volumes are often in close 
proximity to several critical OARs. Specifically, H&N tumours are often concave in 
shape and can wrap around in close proximity to the spinal cord and/or brain stem. 
Additionally, for treatments where the regional lymph nodes are involved, the parotid 
glands can be in close proximity to the targeted volumes. Furthermore, the sheer 
number of additional OARs located in the H&N such as the oral cavity and mandible, 
block many of the potential paths that radiation beams could use to irradiate target 
volumes.  
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1.2. 3D conformal radiotherapy 
Over the past few decades, multiple treatment techniques have been developed in 
attempt improve the quality of radiotherapy in general. 3-dimensional Conformal 
Radiotherapy (3DCRT) uses a linear accelerator (LINAC) to irradiate targeted 
volumes with multiple photon beams directed from various gantry angles around the 
patient. Planning of the beams is performed using 3D patient anatomy data derived 
from a multiple slice computed tomography (CT) scan. The LINAC is fitted with a 
computer controlled multi-leaf collimator (MLC) consisting of two banks of opposing 
tungsten leaves where each leaf is independently positioned to block certain areas of 
the photon beam and create a customised aperture. The planner, with the guidance of 
3D anatomical data, uses the MLC to shape the photon beams to conform to the 
contour of the target volumes and avoid OARs. Multiple beams directed from 
different gantry angles are usually required to produce an acceptable dose distribution. 
3DCRT H&N techniques improve target volume coverage and OAR sparing 
compared to older 2D planning methods [17]. However, H&N 3DCRT techniques are 
not often able to adequately spare the parotid glands, resulting in severe xerostomia. 
Furthermore, the dose distributions generated by 3DCRT can only be convex in 
shape, often not suiting the geometry of H&N planning volumes. Practically, the 
process of generating high quality 3DCRT H&N plans is a time-consuming because 
the process requires multiple manually created plan iterations to find the best plan.  
1.3. Intensity modulated radiotherapy 
Intensity modulated radiotherapy (IMRT) represents a large technological 
improvement for LINAC based radiotherapy treatment. Like 3DCRT, IMRT also uses 
multiple photon beams directed from various gantry angles to produce a conformal 
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dose distribution around the target volumes. However, the key difference between 
3DCRT and IMRT is the method of dose distribution generation. 3DCRT uses beams 
with a uniform or wedged fluence distribution within the MLC defined aperture, 
while IMRT uses beams where the fluence distribution is heterogeneous within the 
aperture [18]. The level of conformality that can be achieved with IMRT is much 
higher than can be achieved with 3DCRT and this allows greater sparing of OARs 
without compromising the dose delivery to the target volumes. Intensity modulation 
of beams can be achieved in two ways: 
 
 Each beam is comprised of multiple subfields called segments (step and shoot 
approach),  
 Dynamic MLC motion is used during the beam delivery (dynamic MLC or 
‘sliding window’ approach).  
 
In the step and shoot approach, each segment has a specified MLC defined aperture 
and an aperture weighting. The MLC defined aperture determines which regions are 
irradiated, while the aperture weight defines the quantity of radiation to be delivered 
through the aperture. The integral dose delivered by a beam comprised of multiple 
segments is calculated as the sum of the dose contributions from each segment. The 
desired intensity modulation for a beam is therefore created by choosing the 
appropriate combination of segments. In the ‘sliding window’ approach, the two 
banks of MLC leaves travel across the field defining a narrow window during 
continuous irradiation. The exact shape and width of the window varies as it travels 
across the field and the LINAC dose rate also varies. In this fashion, the intensity 
modulated distribution is built up. Regardless of the delivery approach used, the 
5 
 
overall IMRT plan is comprised of multiple intensity modulated beams directed from 
various gantry angles. Typically there are five or seven beams.  
1.3.1. Inverse planning 
In theory, a human planner could select the appropriate combination of segments for 
multiple beams to produce the desired dose distribution. This planning approach is 
referred to as forward planning. However in practice, the selection of the appropriate 
segments may not be obvious and it is likely difficult for a planner to generate an 
IMRT plan within an acceptable time frame using a forward planning approach. 
Instead, IMRT plans are generated with an inverse planning approach where the 
segments are determined by computed iterative optimisation [18, 19]. In inverse 
planning, the planner defines dose-volume objectives (DVO) for target and OAR 
volumes representing the dosimetric goals to be achieved by the plan. An example of 
a DVO could be that 98% of the target volume should receive at least a minimum of 
62.7 Gy (i.e. V62.7Gy ≥ 98%). The degree in which a plan accomplishes all of the 
defined DVOs is quantified by an objective function. For a single DVO, the objective 
function is commonly formulated as the square of the difference between the defined 
DVO and the dose/volume achieved by the plan. The total objective function is a 
weighted sum of each of the individual DVO contributions where the weighting 
factors are used to set the relative priority or importance of each DVO. The objective 
function is at a minimum when there is maximum agreement between the defined 
DVOs and the dose distribution that the plan actually produces. An optimisation 
algorithm generates an IMRT plan by iteratively finding the combination of segments 
that minimise the value of the objective function.  
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1.3.2. IMRT Optimisation methods 
There are two primary IMRT optimisation methods: beamlet based optimisation [20] 
and direct aperture optimisation (DAO) [21]. Beamlet based optimisation divides each 
beam into a matrix of smaller beamlets and the beamlet weights are optimised to 
minimise the objective function and produce the specified dose distribution. A 
constraint is imposed during beamlet optimisation to ensure that the optimiser does 
not use negative beamlet weights which are meaningless in reality. The final 
deliverable plan is generated after the optimised beams are translated from the 
theoretical combination of beamlet weights to deliverable aperture shapes using a leaf 
sequencing algorithm. MLC constraints such as leaf positioning restrictions are taken 
into account during the leaf sequencing phase.  
Direct aperture optimisation algorithms optimise aperture shapes and weights directly, 
removing the need for a leaf sequencing step. DAO iteratively creates IMRT beams 
by randomly selecting a parameter (MLC leaf position or an aperture weight) and 
changing that parameter by a random amount. A change is accepted where the change 
reduces the objective function relative to the previous iteration. To avoid becoming 
trapped in the objective function’s local minima, changes that increase the objective 
function are also accepted with a probability that decreases with the number of 
successful iterations.  Changes that violate MLC constraints are not accepted and 
another parameter is selected at random.  
The process is repeated through many plan iterations until a plan of acceptable quality 
is generated and the algorithm is halted.  
1.3.3. IMRT for H&N treatments 
Multiple studies have shown that IMRT produces superior dose distributions for H&N 
treatments compared to 3DCRT [22, 23]. These studies showed that IMRT improved 
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target coverage characteristics compared to 3DCRT by significantly increasing the 
target volume V95% and V90%. The same studies also showed that IMRT can reduce the 
maximum dose delivered to the spinal cord. Additionally, IMRT has been reported to 
reduce the mean dose delivered parotid glands and significantly reduce xerostomia 
related complications [24, 25]. However, H&N IMRT techniques can have long 
treatment delivery times on the LINAC depending on how many beams and segments 
are used by the plan [26]. Additionally, it has been reported that H&N IMRT plans 
can require up to 2.6 times more monitor units (MU) than 3DCRT for dynamic IMRT 
delivery [25]. A potential downside to increased monitor unit utilisation is that the 
patient can be exposed to higher out of field dose. Hall [27] has reported that 
increased to out of field patient exposure due to leakage and transmission radiation is 
a factor that can increase the probability of inducing secondary cancers after 
radiotherapy.  
1.4. Volumetric modulated arc therapy 
Volumetric modulated arc therapy (VMAT) [28] is an evolution of static gantry 
IMRT. Multiple radiotherapy vendors have an implementation of VMAT. For the 
purposes of this study, future use of the acronym VMAT refers to the Varian Medical 
Systems (Palo Alto, USA) implementation of VMAT marketed as RapidArc®. 
Instead of delivering multiple intensity modulated beams from static gantry angles, 
VMAT delivers multiple segments while the gantry is rotated around the patient in a 
continuous arc. As such, in the concept of a static gantry IMRT beam comprised of 
segments is replaced in VMAT by an arc comprised of segments defined at various 
angles around the arc called control points. Like IMRT, each VMAT segment has a 
defined MLC aperture and weight. VMAT is delivered dynamically where the MLC 
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leaves move in synchronisation with the gantry rotation to deliver the planned 
apertures at each control point. The correct aperture weight is delivered by 
modulating the LINAC’s dose rate between 0 MU/min and 600 MU/min. 
Additionally, high aperture weights may require a LINAC dose rate that exceeds 600 
MU/min and the gantry rotation speed is slowed to compensate, ensuring that the 
correct aperture weight is delivered. 
1.4.1. VMAT Optimisation 
VMAT plans are generated using an inverse planning optimisation algorithm first 
developed by Otto [28]. The algorithm uses DAO for optimisation of the segments 
and a progressive sampling method to control the addition of control points to the 
optimisation. Because a VMAT beam is delivered in a continuous arc, efficiency 
constraints for maximum MLC motion and maximum beam weight per degree of 
gantry rotation must be taken into account during optimisation to ensure smooth 
delivery. The MLC motion constraint, determined by the maximum MLC leaf speed 
and the speed of gantry rotation ensures that MLC leaf position changes between 
control points are possible without slowing the gantry rotation speed. The beam 
weight constraint, determined by the maximum LINAC dose rate and the gantry 
rotation speed ensures that beam weights can be delivered without often needing to 
slow the gantry.  Otto realised that optimisation of a particular segment in an arc is 
limited by the two segments on control points either side of the optimised segment. 
This is because the random MLC leaf position and beam weight changes made by 
DAO often exceed the efficiency constraints imposed by the adjacent segments. The 
progressive sampling method used in the VMAT optimisation algorithm overcomes 
this problem by initially optimising only a few segments coarsely spaced around the 
beam. By doing this, the initial optimisation of segments is not restricted by the 
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efficiency constraints and there is a greater chance that the optimiser can find an 
optimal arrangement of segments. However, the integral dose delivered by the beam 
can only be accurately calculated when there are sufficient segments positioned 
around the arc. Therefore, the progressive sampling method begins by optimising 10 
segments and iterates through four further resolution levels where segments are added 
for optimisation. Each successive resolution level doubles the number of segments 
plus one. In the final resolution level, 177 segments are used to approximate a 360 
degree arc.  
1.4.2. VMAT vs. IMRT 
Multiple studies have assessed the differences between VMAT and IMRT for the 
treatment of H&N cancer [29, 30, 31]. It has been reported that VMAT is at least 
equivalent to IMRT in terms of target coverage and OAR sparing. On average VMAT 
treatment delivery times have been reported to be around half that of IMRT. 
Additionally, VMAT H&N plans require around 50% less MU than equivalent IMRT 
plans. 
1.4.3. VMAT uncertainties and quality control 
VMAT is much more complex than 3DCRT in its delivery on the LINAC and 
planning on the treatment planning system (TPS). VMAT delivery involves a 
complex interplay between the gantry rotation, MLC configuration and dose rate. The 
TPS dose calculation for VMAT plans is complex because multiple aspects must be 
correctly modelled such as the MLC characteristics and the dose calculation model for 
small aperture sizes (and more). Additionally VMAT adds many ‘black boxes’ to the 
planning process such as the VMAT optimiser. Therefore there is increased 
uncertainty relating to the agreement between the TPS calculated dose and dose 
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delivered by the LINAC (dosimetric accuracy). As a result, plan specific quality 
control (QC) tests are usually performed to assess whether the predicted dose 
calculated by the TPS is accurately reproduced by the LINAC delivery. These dose 
verification tests of individual plans are usually end-to-end style tests where the 
calculated dose is compared to measurement of the delivered dose using ionisation 
chambers, gafchromic film and diode arrays. The end-to-end tests are global tests of 
the VMAT process from plan optimisation and dose calculation, transfer of the plan to 
the LINAC and delivery of the plan on the LINAC. Additional mechanical QC tests 
are also performed separately to monitor the performance of the LINAC’s VMAT 
delivery such as dynamic MLC and beam output. The agreement between the TPS 
calculated dose and the LINAC delivered dose is one aspect of the total dosimetric 
uncertainty of a VMAT treatment. Other dosimetric uncertainties result from patient 
positioning, inter-fraction patient setup variation, intra-fraction motion and tumour 
growth and shrinkage [32]. Further uncertainty can result from the variability and 
inaccuracies present in contouring of the anatomy and planning volumes by the 
radiation oncologist [33].  
1.3.4. Plan complexity 
Complex IMRT beams have been associated with high MU utilisation, large number 
of segments, small aperture sizes, complicated aperture shapes, high aperture area 
variability and high dose modulation [34, 35, 36, 37]. The negative aspects of high 
complexity IMRT beams are that they take longer to deliver, and the patient is 
exposed to higher amounts of radiation leaking through and scattering off the MLC 
leaves. Additionally, higher complexity beams can degrade the agreement between 
the calculated and measured dose.  However, a certain amount of plan complexity is 
required to create a dose distribution of acceptable quality [38]. How much 
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complexity is needed often depends on the difficulty of the planning problem which is 
determined by the anatomy and planning structures. For example IMRT plans for 
H&N cases are normally more complex than IMRT plans for prostate cases.   
Complexity of VMAT plans have also been associated to the beam characteristics 
previously mentioned for IMRT. Additionally, complex VMAT beams have been 
associated with increased mean leaf travel [39]. Unlike IMRT, the negative aspects of 
high complexity VMAT plans are not so related to delivery inefficiencies but rather 
the degradation of VMAT dosimetric accuracy [39, 40].  
1.5. Purpose of this study 
VMAT is currently used to treat the majority of H&N patients at the Wellington 
Blood and Cancer Centre (WBCC). A total of 113 H&N patients have been treated 
with VMAT since 2012.  The initial implementation of WBCC’s H&N VMAT 
planning protocol has been conservatively designed and purposefully limits plan 
complexity to reduce the likelihood that VMAT dosimetric accuracy is degraded. The 
level of complexity that degrades VMAT dosimetric accuracy is currently not known 
for the WBCC VMAT system. Therefore, one of the objectives of this study is to 
determine whether there is a level of beam complexity that degrades VMAT 
dosimetric accuracy below clinically acceptable tolerances. To do this, beam 
complexity needs to be quantified in some way. As such, this study will also 
investigate the use of metrics derived from beam parameters to quantify complexity. 
Finally, this study will determine whether higher complexity VMAT beams can 
improve the quality of dose distributions used to treat H&N cancer.  
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2. Materials & Methods 
2.1. Treatment Planning 
2.1.1. Selected cases 
Five patients previously treated with H&N VMAT at the WBCC were selected at 
random for this study.  Disease site, TNM disease staging [41] and planning target 
volume (PTV) volumes are listed for each case (table 2.1). The selected patients were 
a representative sample of the H&N cases commonly treated at the WBCC. 
Table 2.1: Summary of the patients included in this study. Disease site, TNM disease staging and PTV 
volumes are listed for each case. 
 
Patient Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
Disease Site Oropharynx 
Oropharynx + 
Tongue 
Hypopharynx Larynx Nasopharynx 
Stage (TNM) T4a,N1,M0 T2,N0,M0 T2,N0,M0 T2,N0,M0 T1,N0,M0 
PTV66 
volume 
(cm
3
) 
190.3 237.5 84.9 158.9 287.6 
PTV54 
volume 
(cm
3
) 
724.6 907.9 421 637.4 750.5 
 
2.1.2. Definition of dose-volume histogram metrics 
Dose-volume histograms (DVH) were used to quantify the dose delivered to each 
planning volume. The following metrics were extracted from the DVH to quantify 
certain characteristics of the dose distribution such as target coverage and OAR dose.  
Dx type metrics indicate the minimum dose delivered to a percentage of a volume (x). 
Additionally, Dxcc type metrics indicate the minimum dose delivered to a volume (x) 
measured in cubic centimetres (cc). Type Vy type metrics indicate the % of a volume 
that receives a minimum dose of at least (y). Dmean type metrics represent the mean 
dose delivered to the entire volume of interest. 
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2.1.3. Definition of planning volumes 
Target volumes 
Delineation of target volumes and OARs was performed by a radiation oncologist 
with CT imaging and additional guidance from positron emission tomography (PET) 
and magnetic resonance (MR) imaging. Delineation of target volumes was in 
accordance with consensus guidelines [42]. Definition of volumes was in accordance 
with International commission on radiation units and measurements (ICRU) 
guidelines [43]. 
The demonstrable extent of the tumour and involved lymph nodes were defined as a 
gross tumour volume (GTV). Potential areas of local extension were defined as a 
clinical target volume (CTV66). Both GTV and CTV66 were prescribed 66 Gy in 30 
fractions. A secondary CTV54 target volume, extending inferiorly on either one or 
both sides of the neck was prescribed 54 Gy in 30 fractions to electively treat 
potential microscopic disease present in the lymphatic pathways.  Planning target 
volumes (PTV66 and PTV54) were defined as 5 mm expansions around the 
corresponding CTVs to account for the uncertainty in patient positioning. For the 
purpose of optimisation, a PPTV66 volume was defined as a subtraction of the GTV 
from the PTV66 and cropped 3mm inside the skin. Similarly, a PPTV54 volume was 
defined as a subtraction of the PTV66 from the PTV54 and cropped 3mm within the 
skin. The PPTV54 volume was also cropped from the PTV66 volume to create a 5mm 
margin between the two volumes. As the PTV54 overlaps the PTV66, the PPTV 
volumes were required to ensure contradicting DVOs were not set that would hinder 
the optimisation. Additionally, the PTVs were cropped 3 mm inside the skin to ensure 
that the optimiser would not attempt to deliver dose to the dose build up regions 
where it is difficult to deposit dose with entrance fluence. VMAT optimisation was 
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performed on the PPTV66, PPTV54 and GTV volumes. WBCC clinical tolerances for 
the PTV volumes are summarised in table 2.2. 
Table 2.2: Clinical tolerances for target volumes. Tolerances are expressed in terms of percentages of 
the prescribed dose for the respective PTV66 and PTV54 volumes. Starting optimisation priority values 
listed are for both target volumes.  For the definitions of DVH metrics see section 2.1.2. 
 
PPTV DVH metric WBCC Tolerance starting optimisation 
priority 
 D98 ≥ 95 % 120 
 D50 100% ± 1.5 % DVO not used 
D2 ≤ 107 % 120 
 
Organs at Risk 
The OARs prioritised to be spared were the spinal cord (SC), brain stem (BS) and 
parotid glands. For oropharyngeal tumours, the SC was the most prominent OAR 
because its 50 Gy tolerance dose level was often in close proximity. A spinal cord 
planning risk volume (SCPRV) was defined as a 5mm expansion around the SC, except 
for the superior edge of the cord where no expansion was made as it directly connects 
to the BS at this position. For nasopharyngeal treatment sites, the BS was often a 
prominent OAR where the target volumes were in close proximity. A brain stem 
planning risk volume (BSPRV) was defined as a 5 mm extension around the BS, except 
for the inferior edge where no extension was made as it directly connects to the SC at 
this position.  PRV volumes were defined for the SC and BS to take into account 
uncertainty and variation in their position because overdosing either could result in 
serious complications. The parotid glands were defined without an extension. The 
parotid glands often partially overlapped with the PTV54 and PTV66 volumes. In this 
situation, the portion of the gland overlapping into the PTV was not used during plan 
optimisation to avoid contradicting DVOs. The portion of the gland not overlapping 
with the PTV was contoured separately and used for optimisation to minimise the 
mean dose to the parotid glands.  Additional to sparing the SC, BS and parotid glands, 
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the dose to the oral cavity, mandible, larynx and pharyngeal constrictors was also 
minimised during optimisation but with lower priority.  
Table 2.3: DVH optimisation objectives for the prioritised and non-prioritised OAR volumes. Starting 
optimisation priority values are listed. For definition of DVH metrics see section 2.1.2. 
 
OAR  WBCC Tolerance Starting 
optimisation 
priority 
Spinal Cord PRV SCPRV D1cc ≤ 50 Gy 70 
Brain Stem PRV BSPRV D1 ≤ 54 Gy 70 
 
Parotid Glands 
Dmean ≤ 26 Gy (Bilateral) 
Dmean ≤ 39 Gy (Ipsilateral) 
Dmean ≤ 25 Gy (Contralateral) 
70 
Oral Cavity Dmean ≤ 45 Gy, D1< 65 Gy 50 
Mandible Dmean ≤ 50 Gy, D1< 70 Gy 50 
Larynx Dmean ≤ 45 Gy, V50Gy< 66 % 50 
Inferior Pharyngeal Constrictor V60Gy< 12% 50 
Middle Pharyngeal Constrictor V60Gy< 75% 50 
Superior Pharyngeal Constrictor V65Gy< 33% 50 
Post Mean Volume should exclude 35 Gy isodose 50 
 
These additional OARs were optimised only when they were originally contoured in 
the clinical plan. A post mean volume, contoured posterior to the SC was used to 
reduce the dose delivered to that region to maintain drainage of the lymph from the 
lymph nodes. The WBCC clinical tolerance doses for the prioritised and non-
prioritised OARs are summarised in table 2.3. 
2.1.4. Plan Quality 
Plan quality was defined in terms of the ability of a plan to deliver the prescribed dose 
to each of the target volumes while simultaneously minimising the dose delivered to 
the OARs. Plan quality was primarily assessed from the dose delivered to both PTV 
volumes as well as the dose delivered to the SC, BS and parotid glands. The dose 
delivered to target and OAR volumes were assessed with the DVH metrics outlined in 
tables 2.2 and table 2.3 respectively. The 3D-dose distribution was also verified using 
the dose colour wash function in eclipse to identify undesirable dose distribution 
features not identified by the DVH. 
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2.1.5. Complexity levels 
A three tier system was developed where plans of increasing complexity were created 
for each case. Only three plans were able to be created for each case to keep the 
project feasible within the allotted time frame. The primary objective of this system 
was to create plans with a wide range of complexity in a well-defined way to 
investigate the relationship between the dosimetric accuracy of plans and plan 
complexity. Additionally, with this approach it was possible to relate the plan 
complexity to the quality of the plan. The clinical plan that was used to treat the 
patient was defined as complexity level one (C1). It was assumed that the clinical 
plans were of relatively low complexity as they were created following a conservative 
planning protocol that used a restrictive MU constraint during optimisation. MUs 
were restricted in the clinical plans as a workaround to minimise the number of 
segments with a MLC leaf opening below the minimum allowed field size of 4 cm
2
. 
For each patient, two more plans of increasing complexity were created, labelled 
complexity levels two (C2) and complexity level three (C3). These complexity levels 
were defined in terms of relative plan quality. C3 plans approximated pareto-optimal 
plans that prioritised coverage of both PTV54 and PTV66 target volumes as well as 
sparing of the SC, BS and parotid glands. Pareto-optimal plans are those where 
further improving one aspect of the plan is impossible without deteriorating another 
aspect of the plan as a consequence [44]. Multiple plan iterations would have to be 
created to find the set of plans that make up the pareto-frontier to completely prove 
pareto-optimality of the plan. However, the C3 plans could not be proven to be truly 
pareto-optimal as creating multiple iterations of the plan was not feasible within the 
allocated time. Instead of selecting a plan from the pareto-frontier, C3 plans were 
selected when it appeared that further plan quality improvements were no longer 
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possible without beginning to compromise other objectives. The C2 plans were 
created to provide a middle ground in plan quality and plan complexity between the 
C1 and C3 plans. The goal for C2 plans was to achieve OAR sparing that was mid-
way between C1 and C3 for the prioritised OARs. This approach assumed that the 
resulting plan complexity would also be half way between C1 and C3 plans. The 
target coverage planning goals for both C2 and C3 plans was to at a minimum match 
the coverage achieved by the C1 plan. Small improvements in target coverage in C2 
and C3 plans were also accepted. As the clinical C1 plans all met the clinical target 
coverage objectives, larger improvements in target coverage were generally not 
possible.  
2.1.6. Progressive Resolution Optimiser 
VMAT plans were generated using the Progressive Resolution Optimiser (PRO) [28] 
module within the Eclipse treatment planning system (figure 2.1).  
The clinical C1 plans were optimised using version 10.0.28 while the majority of C2 
and C3 plans were optimised using version 11.0.31 after a departmental TPS version 
update during this study. For case #5, all C1, C2 and C3 plans were optimised using 
version 10.0.28. Differences between optimiser versions were investigated and the 
results are reported in section 3.2.4. A real-time plot of the DVHs (figure 2.1. : 1) was 
used to assess the dose delivered to each volume involved in the optimisation. During 
optimisation, plan improvements were achieved by manipulating the shape of the 
DVHs with the application of DVOs for each volume involved in the optimisation 
(figure 2.1. : 2). Upper DVOs were used to limit the maximum dose delivered to a 
specified percentage of a volume while lower DVOs were used to ensure a minimum 
dose was delivered to a specified percentage of a volume. Mean DVOs were used to 
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manipulate the mean dose given to the entire volume. Priority numbers (figure 2.1 : 2) 
were used to weight the relative importance of the competing DVOs. 
 
Figure 2.1: The Progressive Resolution Optimiser. Important functions used for plan optimisation are 
numbered 1 to 5. 1: The real time DVH plot. 2: The list of DVOs for the optimisation volumes. 3: the 
real time objective function line plot. 4: the MU objective. 5: the normal tissue objective function. 
 
An objective function line plot available in Eclipse was used to visualise the 
contribution of each volume to the objective function (figure 2.1: 3). Although the 
quantity on the ordinate of this plot in eclipse is not clearly defined or quantified in 
contrast to some other TPS, it represents the value of the optimisation objective 
function. This quantity was used to monitor the progress of the optimisation and to 
assess whether a change to a DVO was achievable by the optimiser indicated by a 
downwards trend of objective function. The controls below the objective function line 
plot were used to select the resolution level to optimise on. Optimisation could be 
performed on a single resolution level using the pause function that stopped the 
optimiser automatically moving to the next resolution level. Resolution levels could 
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also be navigated by using the forward and backwards buttons. The MU used by the 
plan, displayed in the top right corner of the objective function line plot, was used as a 
rough measure of plan complexity during optimisation. The MU objective (figure 2.1 
: 4) was used was during the optimisation of the C1 plans, essentially limiting the MU 
allowed to be used by those plans. By limiting the MU used by the plan, it was 
possible to coarsely restrict the complexity of the plan. For C1 plans, the MU 
objective was set to 500 MU for cases 1, 2, 3, 5 and 400 MU for case 4 as defined by 
the WBCC clinical protocol for each treatment site. The priority number of the MU 
objective was set to 100 for all cases. The MU objective was not used for the 
optimisation of the C2 and C3 plans.  The Normal Tissue Objective (NTO) (fig 2.1 : 
5) was used to ensure that there was adequate dose fall off into normal tissue that was 
not explicitly contoured but located within the body contour. The normal tissue 
objective (NTO) was set to ‘automatic sparing of normal tissue’ and had a priority of 
190 which was unchanged for all plans. The field parameters (table 2.4) used by the 
C1 plans remained the same for the C2 and C3 plans.  
 
Final dose calculation was performed using the Analytical Anisotropic Algorithm 
(AAA) [45, 46] version 11.0.31 for all cases. The Truebeam LINAC beam model was 
calculated from in house WBCC commissioning data. The focal spot size, MLC leaf 
transmission and dosimetric leaf gap beam model have been reported to be the 
important adjustable parameters that affect the AAA dose calculation accuracy of 
small fields [67], like those expected to be found in the generated VMAT plans. The 
focal spot size parameter was set to 0.0 mm, MLC model leaf transmission parameter 
was set to 1.35% and the dosimetric leaf gap parameter was set to 2.0 mm. 
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Table 2.4: The field parameters used by all plans.  
 
Beam Energy Gantry rotation Collimator angle 
CCW 6 MV Photons 179º to 181º CCW 20º 
CW 6 MV Photons 181º to 179º CCW 340º 
 
2.1.7. Generating C3 plans 
C3 plans were generated by re-starting the VMAT optimisation of a copied C1 plan. 
The plan was optimised in a number of iterations whereby the optimisation 
parameters were adapted using the following approach: 
 Prior to starting the optimisation, the monitor unit constraint was turned off as to 
not restrict the complexity of the plan.  
 In the initial optimisation stage, upper and lower objectives were set for the 
PTV66, PTV54 and GTV volumes. DVOs were not defined for OAR volumes to 
first achieve maximum target coverage. For each target volume, a lower objective 
was added at the prescribed dose for 100% of the volume and an upper objective 
at 0.1 Gy above the prescribed dose for 0% of the volume after which the 
optimisation was started. 
 After the initial optimisation stage, target coverage was usually satisfactory with 
the D98, D50 and D2 metrics all well within clinical tolerance. Major changes to the 
DVOs were made with the optimiser paused at resolution level two, where the 
optimiser was still responsive to user changes of DVOs.  
 DVOs were added to the non-prioritised OAR volumes so that they were spared 
similarly to the C1 plan. Subsequently, DVOs were added to the prioritised OAR 
volumes one at a time. Upper objectives that limit the Dmax were used for SCPRV 
and BSPRV volumes while mean objectives were used for parotid glands. Setting 
more stringent DVOs was preferred over changing the priority of the objectives. 
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However, the DVO priority was increased if the optimiser became unresponsive to 
DVO setting changes. The priority values for OAR DVOs generally remained at 
80 or below. The priority values for the target volumes were allowed to increase 
up to 170 where required. Further optimisation of the non-prioritised OARs was 
attempted where applicable, provided that sparing of the prioritised OAR was not 
compromised as a result. 
 As more stringent DVOs were iteratively applied to the OAR volumes, OAR 
doses were decreased and the plan MU was increased. Often at a certain point, 
OAR doses were not able to be further reduced, even though there did not appear 
to be any trade-offs with target coverage. In this situation, the optimiser was 
allowed to progress through to completion and the dose distribution was 
calculated using the AAA algorithm using a 2.5x3.0 mm dose grid resolution.  
Subsequent optimisations utilising the calculated previously calculated AAA dose 
often allowed further OAR dose reductions to be achieved, possibly by moving 
the current plan away from a local minimum. After one or two re-optimisations, 
the plan usually approached an approximate pareto-optimal solution.  This was 
indicated by the observation that further reductions to OAR doses could be made, 
but not without a corresponding degradation of target coverage or increased dose 
to other OARs.  
 
Depending on the case, one of two following methods was used to select the final C3 
plan. Both methods tried to achieve an equal balance between OAR sparing and target 
coverage. 
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1. For cases where minimum clinically acceptable D98 was easily achieved, the C3 
plan was selected when the PTV66 and PTV54 D98 were made to exceed the 
minimum tolerance with some added margin. For example, a PTV66 D98 of more 
than 63.5 Gy was preferred over the minimum 62.7 Gy.  
2. For cases where the minimum PTV66 and PTV54 D98 requirements were 
fundamentally difficult to achieve, the C3 plan was selected when the D98 met the 
minimum clinical tolerance (without added margin).  
 
Concurrently, the PTV D50 and D2 metrics were kept within clinical tolerance. Plans 
violating the clinical tolerances were re-optimised to correct the problem(s) rather 
than applying a global dose renormalisation to the plan. 
 
Generating high quality plans 
To achieve the largest possible OAR dose reductions and best possible target volume 
coverage, it was necessary to use unrealistic DVOs, often resulting in a counter 
intuitive increase in the value of the objective function. For example while optimising 
the C3 plan for case #3, setting the SCPRV Dmax upper DVO to an easily achievable 45 
Gy resulted in a plan that produced an actual Dmax of around 46 Gy. There was close 
agreement between the prescribed objective and the achieved dose, resulting in a low 
contribution to the objective function. However, to dramatically decrease the SCPRV 
dose, a more difficult Dmax objective of ~25 Gy was used, resulting in an actual 
achieved Dmax of around 35 Gy. As the agreement between the prescribed objective 
and achieved dose was poor, the contribution to the objective function was large. 
Therefore, lower OAR doses were often achieved despite increasing the value of the 
objective function. Generally, the rule was to set DVOs well beyond the desired goals 
because the optimiser would never fully achieve the prescribed DVO. As such, focus 
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was placed on the absolute quality of the plan rather the value of the objective 
function itself. 
2.1.8. Generating C2 plans 
Optimisation of the C2 plans were performed similarly to the procedure described 
above. However, instead of aiming to find a pareto-optimal plan, the DVOs were 
adjusted such that the SC D1cc, BS D1, and Parotid Gland Dmean were half way 
between that achieved by the C1 and C3 plans. Target coverage characteristics were 
kept similar to the C3 plan. When a plan had achieved these goals, optimisation was 
completed and the C2 plan was selected.  
2.1.9. Final dose calculation 
After finalising the C2 and C3 plans, the final dose distributions were calculated with 
the AAA algorithm using a 1.0 mm dose grid resolution. For all cases, the assessment 
of plan quality was made with the final dose calculation using AAA version 11.0.31. 
2.1.10. Plan delivery 
VMAT plans were delivered using a Varian Truebeam LINAC equipped with a 120 
leaf Millennium MLC. Leaf width was 5 mm for the central 20 cm of the field and 10 
mm for the outer 20 cm of the field. Maximum MLC leaf speed was 2.76 cm/s [68], 
maximum machine dose rate was 600 MU/min and maximum gantry rotation speed 
was 6 deg/s.  
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2.1. Quantification of plan complexity 
2.2.1. Average Leaf Pair Opening (ALPO) 
A modified version of the average leaf pair opening (ALPO) as defined by Zygmanski 
et al. [47] was used as a measure of the average field size as defined by the MLC 
leaves. First, a leaf pair opening (LPO) was defined as the distance between pairs of 
opposing MLC leaves. Fully closed MLC leaf pairs (LPO=0) were not included in the 
calculation of the ALPO. The ALPO for an individual segment (ALPOs) was then 
calculated using the following equation 2.1: 
 
       
∑ |     |  
  
              (Equation 2.1) 
 
where XR and XL are the MLC positions of the two opposing MLC leaves (right 
bank/left bank),    
          
are the number of open pairs in the segment, j is the index 
for leaf pairs with a non-zero LPO and s is the segment index. Up to 60 leaf pairs 
could be used to collimate the beam with the Truebeam’s Millenium MLC.  
 
Subsequently, the ALPO for a beam (ALPOb) consisting of s segments was calculated 
with equation 2.2:  
 
       
∑       
  
            (Equation 2.2) 
 
where   
        
is the number of segments in the beam, s is the segment index and b 
is the beam index. All beams in this study consisted of 177 segments.  
Finally, the ALPO for a plan consisting of b beams was calculated with equation 2.3:  
 
      
∑       
  
        (Equation 2.3) 
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where   
      is the number of beams in the plan. All plans in this study consisted of 
two beams. 
2.2.2. Critical Leaf Pair Opening (CLPO) 
 
The Critical leaf pair opening (CLPO) metric quantified the proportion of LPOs that 
were smaller than a threshold of 10 mm present in a VMAT plan. Fully closed leaf 
pairs were not included in the calculation. The CLPO for a segment (       was 
calculated using equation 2.4:  
 
       
 
        
      
  
            (Equation 2.4) 
 
 
where 
        
       are the number of LPOs smaller than 10mm in the segment, 
  
          
 are the number of open pairs in the segment and s is the segment index.  
Subsequently, the CLPO for a beam         consisting of s segments was calculated 
with equation 2.5:  
 
       
∑       
  
            (Equation 2.5) 
 
where   
        
is the number of segments in the beam and b is the beam index.  
Finally, the CLPO for a plan was calculated with equation 2.6: 
 
      
∑       
  
           (Equation 2.6) 
 
 
where   
     is the number of beams in the plan and b is the beam index. 
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2.2.3. Mean Leaf Travel (LT) 
The mean leaf travel (LT) metric quantified the mean distance travelled by MLC 
leaves during delivery of a beam. Mean distance travelled by all MLC leaves between 
two segments, s-1 and s (LTs) was calculated with equation 2.7:  
     
∑ |           | 
  
                (Equation 2.7) 
 
where xs and xs-1 are the MLC positions for segment s and segment s-1 respectively, 
  
           is the number of MLC leaves in the segment and l is the leaf index. 
Subsequently, LT for a beam was calculated with equation 2.8: 
 
     
∑     
  
               (Equation 2.8) 
 
where   
        
 is the number of segments in the beams and s is the segment index. 
 
Finally, LT for a plan was calculated with equation 2.9:  
 
 
    
∑     
  
             (Equation 2.9) 
 
where   
     
 is the number of beams in the plan and b is the beam index. 
 
2.2.4. Monitor Units (MU) 
 
The MU used by each plan was recorded from eclipse after dose calculation was 
performed for the finalised plans. Beam MU was correlated against ALPO, CLPO and 
LT. 
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2.3. Verification measurement methods 
2.3.1. Time resolved point dose analysis 
Ionisation chambers and measurement phantom 
Time resolved point dose measurements [48] were made using 0.015 cc and 0.030 cc 
PTW pinpoint ionisation chambers (figure 2.2) [49]. The ionisation chambers were 
cross-calibrated with the WBCC local reference in a 6 MV photon beam in 
accordance with the TRS-398 code of practice [50]. The physical dimensions of the 
chambers and the correction factors used for the calculation of absolute dose are 
displayed in table 2.5:  
Table 2.5: Summary of the physical dimensions and absolute dose calculation / correction factors of the 
0.015cc and 0.030cc PTW Pinpoint ionisation chambers. 
 
Ionisation 
chamber 
Active 
volume 
Dimensions 
length/ 
diameter 
(mm) 
 
Dose to water 
calibration 
factor 
Gy/nC 
(ND,W,Q0) 
 
Ion 
recombination 
correction 
factor (Ks) 
Polarity 
correction 
factor (Kpol) 
Beam 
quality 
correction 
factor 
(KQ,Qo) 
Water to 
plastic 
water 
correction 
factor (Cw) 
PTW 
0.015cc 
Pinpoint 
5.00/1.00 1.204 1.000 0.996 0.993 0.998 
PTW 
0.030cc 
Pinpoint 
5.00/1.45 2.414 1.000 0.999 0.993 0.998 
 
Measurements were made using a 30x30x20 cm plastic water stack (“The original”, 
Computerized Imaging Reference Systems) made up of multiple slabs varying from   
5.0 cm to 0.1 cm in thickness. A cavity drilled into the side of a 2.0 cm thick slab was 
used to position the ionisation chamber at the centre of this slab. Points posterior or 
anterior to the LINAC isocentre were measured by placing the cavity slab either 
higher or lower in the stack. Points superior or inferior to the LINAC isocentre were 
positioned by applying sagittal couch shifts using the couch position read out as a 
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reference. Only one cavity position was available in the cavity slab and the phantom 
was always positioned isocentrically. As a result only points in the sagittal plane 
through the isocentre were measured. 
 
Figure 2.2: 0.015 cc (top) and 0.030 cc (bottom) PTW pinpoint ionisation chambers 
 
Time resolved measurement acquisition 
A PTW T10016 Tandem electrometer provided a polarisation voltage of  
-300V to the ionisation chamber and collected the ionisation chamber signal. Time 
resolved measurement data was obtained by operating the electrometer in continuous 
streaming mode with a time period of 0.1 s using in-house control software [51]. In 
this mode, the electrometer reported the mean measured current (It,av) in amperes over 
each 0.1 s time period (t), allowing for the calculation of time resolved charge in 
coulombs (Qt) with equation 2.10. 
 
                  (Equation 2.10) 
 
The control software saved the time resolved charge data to a comma separated values 
file that would be imported into the analysis software. Prior to, and immediately after 
delivery of the VMAT beam, data was acquired for 60s to later be used for leakage 
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correction of the measurement. Temperature and pressure were monitored for Ktp 
correction [50] of the measurement using the following equation 2.11: 
 
      
                      
           
   (Equation 2.11) 
 
Where Tamb is the measured temperature (ºC) and Pamb is the measured pressure (kPa). 
TPS dose calculation 
A verification plan was created by copying the patient VMAT plan onto a CT data set 
of the plastic water phantom (figure 2.3).  
 
 
Figure 2.3: A screenshot of the verification plan used for TPS dose calculation of point dose and film 
measurements. The HU values of the plastic water structure were overridden to 0 HU. Values of  
-970 HU and -450 HU were assigned to the body and surface of the virtual couch structure respectively 
 
 
The HU values of the plastic water structure were overridden to 0 HU. The centre of 
the plastic water phantom was determined by finding the intersection of three 
radiopaque markers placed on the phantom during the CT scan and was aligned to the 
treatment isocentre.  A virtual couch structure was used to model the attenuation of 
the beam through the treatment couch. Based on WBCC experimental data, values of 
-970 HU and -450 HU were assigned to the body and surface of the couch 
respectively. Measurement points were selected by creating reference points in the 
verification plan. The AAA TPS dose was calculated with a 1.5 mm dose grid 
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resolution. A work around was used to extract the TPS calculated dose per segment as 
eclipse does not provide this data. The verification plan was exported to in-house 
software that converted the 177 segments of each VMAT beam into two new plans 
containing 177 separate static beams each (one for each VMAT beam). The MU 
weight of each static beam was defined as the MU delivered between adjacent control 
points. The MLC configuration of each static beam was defined as the average leaf 
position between adjacent control points.  The converted plans were imported into the 
TPS and dose for both of the reconstructed plans was calculated with a 1.5 mm dose 
grid resolution. After dose calculation, DICOM RT plans now containing segment 
resolved TPS calculated dose data (Ds,tps) for the defined reference points were 
exported to the in-house point dose analysis software.  
 
Segment dose analysis 
Pre-irradiation charge leakage was approximated with linear model fitted to the 60 s 
of data acquired before the VMAT beam delivery and was subtracted from the time 
resolved charge data. Post-irradiation charge leakage was approximated with an 
exponential decay model fitted to the 60 s of data acquired after the VMAT beam was 
delivered and was subtracted from the time resolved charge data [48].  The measured 
time resolved dose (Dt,exp) with equation 2.12:  
 
                                                   (Equation 2.12) 
 
 
where Qt,corr is the leakage corrected time resolved charge,        is the dose to water 
calibration factor for pinpoint ionisation chamber determined in a C-60 beam,       is 
the beam quality correction factor converting the calibration factor from C-60 beam 
quality to the LINAC 6 MV beam quality, Ks is the ion recombination correction 
factor to correct for incomplete charge collection due to ion recombination, Kpol is the 
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polarity correction factor to correct the ionisation chamber response due to a change 
in polarity of the polarisation voltage, Cw is the water-plastic water correction factor 
to account for the measurement being performed in plastic water, Ktp is the 
temperature/pressure correction factor and OC is the correction for LINAC output, 
measured for each session. 
Data contained in the LINAC log files was used to determine the elapsed time where 
the delivery of each segment was completed (Ts). The measured segment resolved 
dose (Ds,exp) was then determined by selecting Dt,exp for times where t=Ts. An 
additional time shift was required to compensate for the difference between the time 
clocks of the various computer systems. As a final step, Ds,exp and  Ds,tps were plotted 
as a function of control point to verify the synchronisation and compare the measured 
and calculated dose for all segments (figure 2.4). This method enabled measurement 
of the delivered dose at each control point of the treatment plan. In this way, observed 
deviations can be correlated to specific machine parameters such as field size, gantry 
angle, and position of the detector relative to the field edge.   
 
Figure 2.4: Segment resolved measured (red) and TPS calculated dose (black) plotted together to assess 
the agreement between measured and calculated segment doses. 
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VMAT dose delivery repeatability 
Segment resolved point dose measurements with a PTW 0.015 cc Pinpoint chamber 
were used to quantify the repeatability [52] of VMAT dose delivery for a C1 plan and 
a C3 plan. The chamber was placed in the plastic water stack phantom and positioned 
at the LINAC isocentre using the patient setup lasers and LINAC cross-wires. 
Repeatability was determined over ten consecutive measurements without altering the 
setup of the phantom and chamber. Phantom temperature and atmospheric pressure 
were monitored throughout the session for Ktp correction of each measurement. 
Segment dose delivery repeatability for each plan was determined by calculating the 
standard deviation for each of the measured segment doses over ten measurements. 
Integral dose delivery repeatability for each plan was determined by calculating the 
standard deviation of ten integral dose measurements.  
 
End-to-end integral dose verification 
The measured integral dose (Dexp) was calculated by summing Ds,exp for all 354 
segments. Using the patient structure set, two measurement points located in PTV and 
an OAR were selected for each plan. The selected points were transferred to the 
plastic water phantom verification plan. Ideally, measurement points were positioned 
in areas where the 3D dose gradients were small to minimise the impact of detector 
positioning errors. This was not always possible for points positioned near OAR 
volumes. A cylindrical contour modelling the size of the pinpoint ionisation 
chambers’ active volume was drawn around each measurement point. The TPS 
calculated integral dose (Dtps) was defined as the mean dose delivered to the chamber 
contour to simulate ionisation chamber volume averaging [53, 54]. AAA dose 
calculation was performed with a 1.0 mm dose grid resolution. The integral dose 
deviation (∆Dint) was calculated with equation 2.13 for all plans. 
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(     –    )
    
       (Equation 2.13) 
 
For each complexity level, the integral dose deviations of OAR and PTV points of 
interest were averaged separately to assess the VMAT dosimetric accuracy for each 
region of interest. Additionally, for each complexity level, integral dose deviations for 
OAR and PTV points were combined into a single average to assess overall VMAT 
dosimetric accuracy. 
 
Sensitivity to phantom positioning  
To assess the sensitivity of point dose measurements to small phantom positioning 
errors, multiple measurements were made with artificially induced setup errors in 
three directions.  
 
2.3.2. EBT3 Gafchromic Film 
Equipment 
EBT3 Gafchromic film dosimetry [55] was used to measure 2D dose distributions at 
coronal dose planes in a 30x30x20cm plastic water stack made up of multiple slabs 
varying from 5.0 cm to 0.1 cm in thickness. In-house developed Matlab software was 
used for analysis of the film dosimetry results. Films were scanned at 72 DPI in 
transmission mode with an Epson 10000XL scanner. A typical scan of an irradiated 
film is displayed in figure 2.5. 
 
Film scanning protocol 
Films were scanned at least 12 hours after the film was irradiated. The irradiated films 
were handled with gloves to avoid contamination and kept in low light conditions. A 
frame was used to ensure films were reproducibly positioned in the scanner. 
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The effect of scanner output variability was reduced with the use of a scanning 
protocol that exploited the warm up characteristics of the scanner as follows: 
 The scanner was warmed up with 30 consecutive scans performed in quick 
succession.  
 Each film was scanned three times in quick succession to compensate for the 
cooling down of the scanner after opening the lid to replace films. 
The third film scan was selected for analysis because the scanner output typically 
stabilised to a reproducible level for this scan. 
 
 
Figure 2.5: A typical scan of an irradiated EBT3 film. The delivered dose distribution is revealed 
by the darkened areas of the film. A frame (grey) was used to ensure films were reproducibly 
positioned in the scanner. 
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Optical density calculation 
Film optical density (ODfilm) was calculated with equation 2.14:  
 
      
        (
      
 
          
 )    (Equation 2.14) 
 
where PVfilm are the pixel values of the scanned film, PVempty are the pixel values of a 
scan without a film present (empty scan) and c is the colour channel (red, green, blue).  
 
The net OD using the red channel (ODnet) was calculated with equation 2.15:  
 
      
      
 
      
  
       
 
       
      (Equation 2.15) 
 
where ODblank, representing the OD of a non-irradiated film was subtracted from the 
experimental film OD (ODfilm). Additionally, film specific thickness variation was 
corrected by dividing red channel OD by the blue channel OD. The net OD was 
subsequently used for dose calculation. 
 
Sensitometric curve 
A calibration film was created by irradiating a film at 5cm depth in plastic water 
(95cm SSD) with a jaw defined step-wedge plan producing ten increasing dose levels 
ranging from ~0.0 Gy to ~3.9 Gy along the superior/inferior axis (figure 2.6). The 
reference calibration dose was generated from the step-wedge TPS AAA dose 
calculation after the plan was modified to match central axis ionisation chamber 
measurements of the dose levels. 
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Figure 2.6: An example of a step-wedge calibration film. Ten dose levels from ~0.0 to ~3.9 Gy were 
created with a jaw defined step-wedge plan.  
 
The sensitometric curve relating dose to net OD was modelled with a gamma 
distributed single hit model [56] (equation 2.16.):  
 
          
              
        (Equation 2.16) 
 
where D(OD)i is the sensitometric curve, ai, bi, and ci are the curve fitting parameters 
and ODi is the net OD. The model was extended such that each lateral position of the 
film (i) had an individually calculated sensitometric curve allowing for the effective 
removal of lateral position scanning artefacts. The fitting parameters (ai,bi,ci), 
described by second degree polynomial functions with dependence on lateral position 
were found by optimising the fit between the measured and reference calibration dose 
using the Levenberg-Marquardt least-squares curve fitting algorithm [57, 58]. The 
generated fitting parameters were saved as a calibration set to be referenced for the 
dose calculation of measurement films. 
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End-to-end integral dose verification 
Film analysis used the same verification plan that was used for point dose analysis, 
described in section 2.3.1. Two film measurement planes were defined by creating 
reference points at the depth of the plane of interest in the verification plan. Film 
planes were selected at the same depths where point doses were measured so dose 
measured by the two methods could be compared.  The AAA TPS dose was 
calculated with a 1.0 mm dose grid resolution.  
The measurement film, blank film, empty scan, calibration set and TPS plan/dose 
matrix were imported into the film analysis software. TPS calculated dose was 
corrected to account for the LINAC output on the day of the film measurement. 
Measured film dose planes were compared to TPS calculated dose planes with gamma 
analysis [59] using dose deviation of 2% (∆D = 2%) and distance to agreement of  
2 mm (DTA = 2 mm) criteria. ∆D values were calculated relative to the average dose 
delivered to the high dose area of the film (80% of the 99th percentile film dose) that 
approximated the PTV in the dose plane. An isodose threshold of 50% of the 
maximum plane dose was used for gamma analysis of both PTV and OAR planes. 
Film results of different plans were compared with gamma pass rates and mean 
gamma values. For each complexity level, gamma pass rates and mean gamma values 
for OAR and PTV planes were averaged separately to assess VMAT dosimetric 
accuracy for each region of interest. Additionally, for each complexity level, gamma 
pass rates and mean gamma values for OAR and PTV planes were combined into 
averages to assess overall VMAT dosimetric accuracy. 
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2.3.3. ArcCheck 
Equipment 
End-to-end integral dose verification measurements were performed using the 
ArcCheck cylindrical diode array phantom (figure 2.7) [60, 61]. The ArcCheck had 
1386 diode detectors arranged helically at a depth of 2.9 cm in a cylindrical acrylic 
(PMMA) phantom. Adjacent diodes were spaced 1.0 cm apart. An acrylic insert was 
used to fill the air gap located in the centre of the cylinder. The SNC Patient software 
[61] was used to control the device during data acquisition and was also used to 
perform gamma analysis between the measured and calculated diode doses. 
 
 
Figure 2.7: The ArcCheck diode array. Visible is the central acrylic insert and the external alignment 
markers used to position the phantom at isocentre. 
 
ArcCheck Calibration  
The ArcCheck dose calibration was performed by irradiating two calibration diodes 
with a 200MU, 10x10cm 6MV photon field. AAA TPS dose calculation of the 
calibration setup was used to determine that 267cGy/200MU was delivered to the 
calibration diodes.  Immediately after irradiating the ArcCheck with the calibration 
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field, the TPS calculated calibration dose was entered into the SNC patient software to 
convert the calibration diode meter readings into dose, creating an absolute dose 
calibration file.  The remaining diodes were calibrated relative to the calibration 
diodes using an array calibration file. The stability of the array calibration was 
monitored with by irradiating the ArcCheck with a conformal arc each month. 
 
TPS dose calculation 
A verification plan was created by copying a VMAT plan onto a CT scan of the 
ArcCheck phantom. A TPS HU override was not applied to the phantom structure and 
the ArcCheck heterogeneity correction was turned off in SNC patient. The central 
reference point of the ArcCheck was determined by finding the intersection of three 
radiopaque markers placed on the ArcCheck’s external positioning lines during the 
CT scan and was aligned to the treatment isocentre. A virtual couch structure was 
used to model the attenuation of the beam through the treatment couch. Based on 
WBCC experimental data, values of -970 HU and -450 HU were assigned to the body 
and surface of the couch respectively.  AAA dose calculation was performed using a 
1.0 mm dose grid resolution. The calculated dose matrix and RT plan were exported 
in DICOMRT format to be imported into the SNC patient software. 
 
Sensitivity to phantom positioning  
Systematic phantom shifts were applied in three directions to assess the impact of 
positioning errors on ArcCheck results.  
 
Plan measurement  
The ArcCheck was positioned at the LINAC isocentre and calibrated. All 30 plans 
were measured in a single three hour session. To minimise variation of the results due 
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to phantom positioning, measurements were performed on all 30 plans without 
altering the setup of the phantom between measurements.  
 
Analysis 
TPS calculated dose was imported into the SNC patient software. Agreement between 
measured and calculated dose was quantified with gamma analysis using gamma 
criterion ∆D=2% and DTA = 2mm and a dose threshold of 10%. Absolute dose mode 
was used with the Van Dyk ∆D calculation turned on. Software calculated alignment 
shifts were not used.  Gamma pass rates were averaged for C1, C2 and C3 plans to 
assess VMAT accuracy for the three complexity levels.  
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3. Results 
For the following results, differences between complexity levels were analysed with a 
series of statistical significance tests. With the small sample size of five cases, 
differences with statistical significance (p<0.05) could not be proven. However, clear 
trends in the data were observed and these are reported where the result was 
consistently observed for all cases. It is estimated that three more cases displaying 
similar results would allow for significance to be proven.  
3.1. Plan quality 
In the following section, plan quality indicated by DVH metrics (described in section 
2.1.2.) for target coverage and OAR sparing are reported for all complexity levels. 
DVH metrics are an efficient method to compare plans, but important spatial details 
of the dose distribution may be missed. Therefore, in addition, typical features of the 
dose distributions created by C1, C2 and C3 plans are illustrated.  
3.1.1. Target coverage 
PTV66 and PTV54 D98, D50, and D2 DVH metrics are displayed for all complexity 
levels in table 3.1. Relative to the C1 plans, the C2 and C3 plans consistently 
increased the PTV66 D98 for all cases, but the magnitude of the increase varied from 
case to case. On average, C2 plans increased the PTV66 D98 by 0.7 ± 0.4 Gy (1 S.D.), 
while C3 plans increased the PTV66 D98 by 0.6 ± 0.3 Gy. Despite all three complexity 
levels having similar PTV54 D98 and D2 metrics, C2 and C3 plans consistently 
produced PTV54 D50 that was closer to 54 Gy than the C1 plans indicating increased 
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dose uniformity.  No other consistent trends with complexity level were observed for 
the other PTV54 and PTV66 DVH metrics.  
Table 3.1: Target coverage DVH metrics comparison between C1, C2 and C3 plans for PTV66 and 
PTV54 volumes. Metrics are expressed as mean (range). Wilcoxon matched-pair signed rank test (two 
tailed) p-values are listed for C1 vs. C2 and C1 vs. C3. For definition of DVH metrics see section 2.1.2. 
 
Complexity level C1 C2 C3 C1/C2 
p 
C1/C3 
p 
PTV66      
D98 (Gy) 62.9 (62.4-63.3) 63.6 (62.5-64.1) 63.5 (62.7-64.0) 0.063 0.058 
D50 (Gy) 66.2 (65.8-67.0) 66.2 (65.9-66.7) 66.1 (65.9-66.9) 0.892 0.462 
D2 (Gy) 68.1 (67.5-69.6) 68.1 (67.6-69.0) 68.1 (67.7-69.5) 0.685 0.855 
PTV54      
D98 (Gy) 51.6 (51.3-52.0) 51.9 (51.2-52.4) 51.8 (51.0-52.3) 0.201 0.269 
D50 (Gy) 54.5 (54.2-55.0) 54.3 (53.9-55.1) 54.2 (53.8-54.8) 0.136 0.058 
D2 (Gy) 56.7 (56.0-57.6) 56.7 (56.0-58.0) 56.7 (56.2-57.5) 0.855 1.000 
 
3.1.2. OAR sparing 
Spinal cord, brain stem and parotid gland DVH metrics for all complexity levels are 
displayed in table 3.2. Relative to C1 plans, C2 and C3 plans reduced the SC D1cc by 
on average 5 ± 2 Gy and 10 ± 3 Gy respectively. Additionally, on average C2 and C3 
plans increased the minimum distance from the SCPRV to the critical 50 Gy isodose by 
1.1 mm (0.5 mm to 2.0 mm) and 1.8 mm (1.5 mm to 6.0 mm) respectively.  For cases 
where the target volumes were in close proximity to the brain stem, C2 and C3 plans 
decreased the BS D1 on average by 6 ± 1 Gy and 10 ± 3 Gy. For cases where the brain 
stem was not in close proximity to the target volumes, the brain stem dose was not 
explicitly optimised and no further dose reduction was observed. For cases where the 
C1 treatment plans produced mean parotid doses greater than 20 Gy, the 
corresponding C3 plans reduced parotid gland mean dose by 6 to 8 Gy. C3 plans 
made smaller parotid dose reductions (2 to 4 Gy) where the corresponding C1 plans 
produced doses less than 15 Gy. Improved sparing of the prioritised OARs made by 
C2 and C3 plans was consistently observed for all cases.   
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Table 3.2: OAR DVH metrics comparison between C1, C2 and C3 plans for Spinal Cord, Brainstem, 
left Parotid Gland and right Parotid Gland. Metrics are expressed as mean (range). Wilcoxon matched-
pair signed rank test (two tailed) p-values are listed for C1 vs. C2 and C1 vs. C3. For definition of 
DVH metrics see section 2.1.2. 
 
Complexity level C1 C2 C3 C1/C2 
p 
C1/C3 
p 
Spinal Cord PRV      
D1cc (Gy) 42.8 (41.5-43.5) 38.6 (37.0-42.0) 31.6 (28.8-35.4) 0.063 0.063 
Min. Distance to 50 
Gy isodose (mm) 
1.4 (1.0-3.0) 2.5 (1.5-4.0) 3.2 (1.5-6.0) 0.054 0.058 
Brainstem PRV      
D1 (Gy) 28.8 (5.0-49.7) 26.3 (5.7-48.8) 23.1 (5.9-43.1) 0.313 0.313 
Left Parotid      
Dmean (Gy) 18.5 (8.0-28.1) 16.9 (9.8-25.2) 14.2 (8.1-22.0) 0.188 0.125 
Right Parotid      
Dmean (Gy) 17.3 (12.0-26.6) 16.9 (11.4-26.6) 14.5 (10.4-21.1) 0.100 0.058 
 
The dose given to non-prioritised OARs was not increased as a consequence of the 
focus put on reducing the prioritised OAR doses. C2 and C3 plans produced non-
prioritised OAR doses that were at least as low as what was achieved with the C1 
plans. Mean oral cavity dose (calculated for five cases) was similar for all complexity 
levels (22 ± 9 Gy). The mandible dose was calculated for two cases. For case #4 the 
mandible dose was similar for all complexity levels while for case #5 the C3 plan 
reduced the mandible dose by 5 Gy. 
In specific cases where sparing was possible, there were noteworthy improvements in 
sparing of the larynx and pharyngeal constrictors.  The C3 plan for case #5 decreased 
the larynx dose from 50.7 Gy (C1 plan) to 35.0 Gy. A smaller 5.8 Gy decrease was 
achieved by the C3 plan for case #1. Finally, the C3 plan for Case #2 reduced the 
pharyngeal constrictor dose by 5.8 Gy.  
3.1.3. Case Study 
In this section, case #1 is presented to illustrate the effect plan complexity typically 
had on the dose distributions of an individual patient. Cumulative dose volume 
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histograms comparing C1, C2 and C3 plans are plotted in figure 3.1 and DVH metrics 
are displayed in table 3.3. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.1: Cumulative dose volume histograms for case #1, comparing C1 (solid lines), C2 (dashed 
lines) and C3 (dotted lines) plans. DVHs for PTV66, PTV54, Spinal Cord (SC), Brainstem (BS), left 
Parotid Gland (LP) and right Parotid Gland (RP) are shown in their respective colours. 
 
For this case, the C2 and C3 plans showed improvement in both target coverage and 
OAR sparing. The C2 and C3 plans increased the PTV66 D98 by 1.1 Gy and 1.0 Gy 
respectively. The C2 and C3 PTV66 DVH dropped off more steeply without 
compromising the D50 or increasing D2 indicating a more homogeneous dose 
distribution. Similarly, C2 and C3 plans increased the PTV54 D98 by 0.4 Gy and 0.3 
Gy respectively. Similar to the PTV66 DVH, The C2 and C3 PTV54 DVH also 
dropped off more steeply than the C1 plan. 
 
The C2 and C3 plans decreased the SC D1cc by 4.5 Gy and 9.4 Gy respectively. 
Similarly, the C2 and C3 plans reduced the BS D1 by 7.1 Gy and 11.4 Gy 
respectively. The C2 and C3 plans reduced the mean left parotid gland dose by 2.9 Gy 
and 6.1 Gy respectively. The C3 plan decreased the mean right parotid gland dose by 
2.0 Gy while the C2 plan produced a negligible 0.2 Gy decrease. 
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Table 3.3: Target volume and OAR DVH metrics for the C1, C2 and C3 plans of case #1. For 
definition of DVH metrics see section 2.1.2. 
 
Complexity level C1 C2 C3 
PTV66    
D98 (Gy) 63.0 64.1 64.0 
D50 (Gy) 65.8 65.9 65.9 
D2 (Gy) 67.5 67.6 67.7 
PTV54    
D98 (Gy) 52.0 52.4 52.3 
D50 (Gy) 54.3 54.1 54.1 
D2 (Gy) 56.1 56.2 56.2 
Spinal Cord PRV    
D1cc (Gy) 41.5 37.0 32.1 
Min. Distance to 50 Gy 
isodose (mm) 
3.0 4.0 6.0 
Brainstem PRV    
D1 (Gy) 36.2 29.1 24.8 
Left Parotid    
Dmean (Gy) 28.1 25.2 22.0 
Right Parotid    
Dmean (Gy) 19.8 19.6 17.8 
 
The dose reduction to OAR volumes was a result of increased dose fall off between 
the target volume and the respective OAR.  Sagittal plane dose distributions through 
the centre of the SCPRV volume illustrate the dose fall off achieved by the three 
complexity levels (figure 3.2). It can be seen that along the entire length of the spinal 
cord, the steepness of the dose fall off from PTVs was increased with higher 
complexity plans. Additionally, with increasing plan complexity the minimum 
distance from the proximal edge of the SCPRV to the 50 Gy isodose increased from 
3mm (C1) to 4mm (C2) and 6mm (C3) (figure 3.3). The dose reduction to the spinal 
cord and region posterior to the spinal cord is also visible on the transverse plane 
(figure 3.4). Improved sparing of larynx is visible on the sagittal plane where the C2 
and C3 plans decreased the mean larynx dose from 49.3 Gy (C1 plan) to 45.2 Gy and 
43.5 Gy respectively. The transverse plane dose distributions (figure 3.4) show that 
the reduction in parotid gland dose was achieved with increased dose fall off localised 
in the regions between the target volumes and the parotid glands.   
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Figure 3.2: Sagittal plane dose distributions through the centre of the spinal cord PRV volume (yellow 
contour).  Increased plan complexity produced steeper dose drop off from the PTV66 volume (purple 
contour), resulting in a reduction to the SC PRV D1cc. 
 
 
 
 
 Figure 3.3: Sagittal plane dose distributions through the centre of the spinal cord PRV volume (yellow 
contour).  Higher plan complexity increased the minimum distance from the proximal edge of the SC 
PRV to the 50 Gy isodose (black isodose) from 3mm (C1) to 4mm (C2) and 6mm (C3).  
 
 
 
 
Figure 3.4: Transverse plane dose distributions through the left (Yellow contour) and right (Coral 
contour) parotid glands. Increased plan complexity produced steeper dose drop off from the PTV66 
(blue contour) and PTV54 volumes (red), reducing the mean dose to the left and right parotid glands. 
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3.2. Plan complexity 
The planning strategy using complexity levels produced three distinct categories of 
plans defined by plan quality. In order to study complexity in relation to verification 
measurement results, the fundamental parameters of the plans were quantified with 
complexity metrics.  Complexity metrics calculated for each complexity level were 
used to quantify MLC motion and the field sizes defined by MLC apertures. Dose rate 
and gantry speed modulation were analysed by plotting both parameters for each 
segment. The calculated parameters were related back to the MU used by the beam so 
that MU may be used as an informed guide of complexity during optimisation.   
3.2.1. Complexity metrics 
The complexity metrics for the counter clockwise (CCW) and clockwise (CW) beams 
are plotted separately in figure 3.5. For all cases, the complexity metrics displayed 
clear trends with complexity level. All metrics also displayed considerable variation 
from case to case, indicating that patient specific factors such as the relative location 
and size of planning volumes may also play a role in defining the complexity of the 
beams. 
Monitor Units 
The mean MU utilised by C1, C2 and C3 plans was 444 ± 36 (1 S.D.), 578 ± 41 and 
683 ± 49 respectively. Increased MU utilisation with higher complexity level plans 
was consistently observed with both CCW and CW beams for all cases. The variation 
in MU utilisation between cases increased with complexity level for CW beams but 
not for CCW beams. On average, the CW beam used 19 ± 26 (1 S.D.) more MU than 
the CCW beam (figure 3.6), indicating that the complexity of each pair of beams may 
not be equal 
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ALPO & CLPO 
For both beams, ALPO decreased, and CLPO increased with complexity level, 
indicating that smaller fields were utilised in the higher complexity beams. The mean 
ALPO for C1, C2 and C3 plans was 41 ± 5 mm, 32 ± 6 mm and 29 ± 6 mm 
respectively. Decreased ALPO with higher complexity level plans was consistently 
observed with both CCW and CW beams for all cases. The mean CLPO for C1, C2 
and C3 plans was 16 ± 5 %, 24 ± 9 % and 29 ± 9 % respectively.  
 
 
Figure 3.5: Box plots of complexity metrics, MU, ALPO, CLPO and LT against complexity level. 
Median values are plotted with first and third quartiles. Whiskers represent the range of data within 1.5 
times the inter-quartile range. Outliers, plotted as black dots are defined as data outside 1.5 times the 
inter-quartile range. 
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Increased CLPO with higher complexity level plans was consistently observed with 
both CCW and CW beams for all cases. Like beam MU, there were differences 
between the CW and CCW beams for the ALPO and CLPO10mm metrics. On average, 
the ALPO was 3 ± 5 mm lower for CW beams for CCW beams and the CLPO was 5 
± 5% higher for CW beams than for CCW beams (figure 3.6). 
 
Leaf travel 
 
LT primarily increased from levels C1 to C2. A smaller increase was seen from C2 to 
C3 for the CW beams while no increase was observed for the CCW beams. The mean 
LT for C1, C2 and C3 plans was 658 ± 94 mm, 742 ± 91 mm and 760 ± 76 mm 
respectively. On average, LT was higher by 12 ± 18 mm for CW beams than for CCW 
beams  
 
Figure 3.6: Histograms illustrating differences between CW and CCW beams for MU, ALPO, CLPO 
and LT complexity metrics. The red dashed line indicates the mean difference between CW and CCW 
beams. 
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3.2.2. ALPO, CLPO, LT relationships with MU 
ALPO, CLPO and LT were correlated with beam MU (figures 3.7, 3.8, 3.9). ALPO 
displayed a negative linear trend with beam MU (r
2
= 0.62), indicating that an increase 
in beam MU corresponds with a decrease in average field size. The CLPO metric 
displayed a positive linear trend with beam MU (r
2
= 0.53) indicating that there was 
also an increase in the proportion of LPOs smaller than 10 mm with increased beam 
MU. A linear trend also existed between LT and beam MU (r
2
= 0.27). This 
correlation was much weaker than the two other metrics, but on average, beams with 
higher MU did show higher LT. 
 
 
Figure 3.7: ALPO plotted against MU for all beams. r
2 
was 0.62 for the fitted linear model. 
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Figure 3.8: CLPO plotted against MU for all beams. r
2
was 0.53 for the fitted linear model 
 
 
Figure 3.9: LT plotted against MU for all beams. r
2 
was 0.27 for the fitted linear model. 
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3.2.3. Case study 
Continuing the case study started in section 3.1.3, the complexity metrics for case 
#1’s C1, C2 and C3 plans are listed in table 3.4. 
 
Table 3.4: Complexity metrics for case #1’s C1, C2 and C3 plans. 
Complexity Level C1 C2 C2 
Plan MU 437 621 690 
ALPO (mm) 41 30 26 
CLPO (%) 19% 28% 33% 
LT (mm) 707 803 824 
 
3.2.4. TPS version 11 upgrade 
The eclipse TPS was unavoidably upgraded from version 10.0.28 (v10) to version 
11.0.31 (v11) before the majority of the C2 and C3 plans were generated. As a result, 
all C1 plans were optimised using v10 while the majority of C2 and C3 plans were 
optimised in v11. The exception was case #5 where all plans were optimised using 
version 10. The major differences between the two optimiser versions appeared to be 
that the v10 optimiser produced plans with a more continuous style dose rate while 
v11 optimiser generated plans with a more step-like style dose rate (figure 3.10). It 
was important to ensure that the new optimiser version also did not fundamentally 
change the other complexity metrics: MU, ALPO, CLPO and LT. To investigate 
whether the new TPS version introduced new optimisation behaviour, three similar 
quality plans from the same case were compared.  Plan “v10orig” was the original v10 
clinical plan, plan “v10reopt” was a re-optimised plan using v10 and plan “v11reopt” was 
a re-optimised plan using v11 and the same optimisation objectives as v10reopt. By 
performing a re-optimisation of the plan using v10 (v10reopt), the effect of a re-
optimisation using similar but potentially different optimisation objectives could be 
observed for the same optimiser version. The re-optimisation of v11reopt was 
performed to observe the differences between optimiser versions with identical 
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optimisation objectives. This comparison of three plans was made for three different 
H&N cases (independent of the five included in the complexity study). 
It was found that the step-like dose rate could only be found in the plans generated 
with the v11 optimiser. Additionally, Case #5’s C2 and C3 plans (optimised in v10) 
had a continuous dose rate like the other v10 plans indicating that the new optimiser 
version was the primary cause of this effect. The differences between the optimiser 
versions were negligible for the MU, ALPO and CLPO metrics. Larger differences 
were observed between v10, v10reopt and v11reopt for leaf travel. However, LT was also 
changed for the v10reopt plans implying that LT can change as a result of re-
optimisation alone.  
 
Figure 3.10: Dose rate modulation for CCW and CW beams optimised with: eclipse version 10 original 
optimisation (top), version 10 re-optimisation (middle) and version 11 re-optimisation (bottom). 
V10 optimisations displayed a continuous style dose rate modulation while the V11 optimisation 
displayed a “step-like” dose rate modulation. Re-optimisation of the plan was seen to change the 
magnitude, frequency and location of dose rate modulation.  
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3.3. Plan dosimetry verification 
3.3.1. VMAT delivery repeatability 
Ten consecutive time resolved point dose measurements were used to assess the 
repeatability of a C1 plan delivery while nine measurements (data for one run was 
corrupted) were used for a C3 plan delivery (using case #5 plans). The measured 
integral dose for both sets of measurements is shown in table 3.5.  
Table 3.5: Results of the repeatability experiments for the integral measured dose. Mean integral 
measured dose and standard deviations for the C1 and C3 plans are displayed. 
Plan C1 C3 
Average measured integral dose (cGy) 196.0 194.0 
Absolute standard deviation (cGy) 0.06 0.05 
Relative standard deviation  < 0.1% < 0.1% 
 
The relative standard deviation of the integral dose was less than 0.1% for both sets of 
measurements.  The average measured segment dose is plotted against control point 
for the C1 plan (figure 3.11) and C3 plan (figure 3.12). Control points 1-177 represent 
the first beam while control points 178-354 make up the second beam. The standard 
deviation of segment resolved dose measurements was calculated for all 354 
segments. Red error bars (1 S.D.) are plotted with the average segment dose (figures 
3.11 & 3.12, top), but are not easily seen on this scale. The average relative standard 
deviation per segment was 0.6% for the C1 plan and 0.5% for the C3 plan. Log file 
analysis shows that MLC position deviations were within ± 0.6mm for both plans. 
Log files reported that gantry rotation errors were ± 0.15º at the start and end of the 
arc and less than 0.05º while the rotation speed was constant. It is important to note 
that deviations calculated from LINAC log files represent deviations measured by the 
LINAC control systems, but do not take into account deviations due to error in 
calibration. These results indicate that the Truebeam LINAC can deliver VMAT with 
excellent repeatability in terms of both the segment dose and the integral dose.  
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Further, no difference in dose delivery repeatability was found between the low 
complexity and high complexity plans. 
 
Figure 3.11: C1 plan. The average (of ten measurements) measured segment dose plotted against 
control point (top). The standard deviation plotted against control point (bottom). The average segment 
relative standard deviation was 0.6%
Figure 3.12: C3 plan. The average (of nine measurements) measured segment dose plotted against 
control point (top). The standard deviation plotted against control point (bottom). The average segment 
relative standard deviation was 0.5% 
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3.3.2. Impact of dose grid resolution 
The impact of dose grid resolution on the calculated dose was determined through 
comparison of point doses for 1.0 mm and 1.5 mm dose grid resolutions. 
When the dose calculation grid resolution was reduced from 1.5 mm to 1.0 mm, TPS 
calculated point doses were reduced by 0.9% ± 0.4% for C1 plans, 1.0% ± 0.3% for 
C2 plans and 1.2% ± 0.4% for C3 plans.  Qualitative comparison of the 1.5 mm and 
1.0 mm calculated dose using dose profiles showed that the decrease in dose was 
generally a systematic drop for all areas of the dose distribution. Dose calculation 
using 1.0 mm dose grid resolution gave the best agreement between measured and 
calculated dose for all end to end verification methods and therefore was used for 
analysis of all end-to-end dose verification measurements.  
3.3.3. Point dose verification 
Sensitivity to phantom positioning  
To assess the sensitivity of point dose measurements to small phantom positioning 
errors, multiple measurements were made with artificially induced setup errors in 
three directions. It was found that measurements made in large dose gradients were 
more sensitive to positioning errors than measurements made in small dose gradients. 
Effectively, a position offset from the nominal measurement point would result in the 
measurement of a different part of the dose distribution. From these observations, it 
was expected that measurements made in large dose gradients (e.g. OAR regions) 
would have higher uncertainty than measurements made in small dose gradients (e.g. 
PTV regions). Therefore, measurements performed in OAR and PTV regions were 
analysed separately. 
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Integral point dose analysis 
Average point dose deviations for PTV points, OAR points and all points combined, 
for all three complexity levels are summarised in table 3.6. All point dose results were 
within clinically acceptable limits. No significant differences in the average point 
dose deviations were observed between complexity levels. 
 
Segment point dose analysis 
Analysis of the dose deviation per segment using the methodology described by 
Louwe et al. [48] did not reveal significant systematic differences between the three 
complexity levels. As an example, segment deviations (PTV points) expressed as a 
percentage of the fraction dose for are displayed as a function of the detector distance 
to the closest field edge (figure 3.13). The only deviations that could be observed 
above the background noise level were for segments where the detector was located 
near the beam penumbra. 
 
 
Table 3.6: Average point dose deviations for PTV points, OAR points and all points combined for C1, 
C2 and C3 plans. Matched-pair t-test (two tailed) p-values are listed for C1 vs. C2, C1 vs. C3 and C2 
vs. C3 
 
Complexity level C1 C2 C3 C1/C2  
p 
C1/C3  
p 
C2/C3  
p 
PTV points  
Mean deviation  ± 1 S.D. -0.4% ± 0.8% 0.4% ± 0.7% 0.3% ± 0.8%  0.170 0.241 0.802 
OAR points  
Mean deviation  ± 1 S.D. 0.2% ± 1.1% -0.6% ± 1.5% -0.3% ± 1.6% 0.136 0.299 0.404 
All points  
Mean deviation  ± 1 S.D. -0.1% ± 1.0% -0.1% ± 1.2% 0.0% ± 1.2% 0.933 0.769 0.758 
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Figure 3.13: Segment point dose deviations (PTV points) expressed as a percentage of the fraction dose 
are displayed as a function of the detector distance to the closest field edge. The largest deviations 
occurred where the detector was measuring in the beam penumbra. 
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3.3.4. Film dose verification 
Coronal plane film dose analysis 
 
Gamma analysis (2%, 2mm criterion) was performed between the measured film dose 
and calculated TPS dose for each measurement plane. Average gamma pass rates and 
mean gamma values calculated for PTV planes, OAR plans, and all planes combined, 
for all three complexity levels are summarised in table 3.7. All film results were 
within clinically acceptable limits.  No significant differences in gamma pass rate and 
mean gamma was observed between the three complexity levels for all measurement 
planes. OAR planes tended to have slightly lower gamma pass rates and higher mean 
gamma values than the corresponding PTV planes for a given plan. Point doses 
(voxels) extracted from the film were within 2% of the corresponding ionisation 
chamber point dose measurement 
 
Table 3.7: Average film gamma pass rates (2%, 2mm criterion) and mean gamma values for PTV 
planes, OAR planes and all planes combined for C1, C2 and C3 plans. Wilcoxon matched-pair signed 
rank test (two tailed) p-values are listed for C1 vs. C2, C1 vs. C3 and C2 vs. C3 
 
Complexity level C1 C2 C3 C1/C2  
p 
C1/C3  
p 
C2/C3  
p 
PTV planes  
Mean γ pass rate  ± 1S.D. 96% ± 2% 96% ± 2% 97% ± 1% 0.586 0.410 0.572 
Mean γ ± 1S.D. 0.25 ± 0.05 0.24 ± 0.04 0.23 ± 0.01 0.625 0.343 0.784 
OAR planes  
Mean γ pass rate  ± 1S.D. 94% ± 3% 94% ± 2% 94% ± 1% 0.789 1.000 0.490 
Mean γ ± 1S.D. 0.30 ± 0.07 0.32 ± 0.06 0.31 ± 0.04 0.458 0.625 1.000 
All planes  
Mean γ pass rate  ± 1S.D. 95% ± 3% 95% ± 2% 96% ± 2% 1.000 0.606 0.470 
Mean γ ± 1S.D. 0.27 ± 0.06 0.28 ± 0.07 0.27 ± 0.05 0.357 0.123 0.601 
 
3.3.5. ArcCheck dose verification 
Sensitivity to phantom positioning  
Systematic phantom shifts were applied in three directions to assess the impact of 
positioning errors on ArcCheck results. Lateral phantom shifts from the nominal 
position at isocentre decreased gamma pass-rates (2%, 2mm) by 4% per mm shift. 
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Anterior/Posterior shifts from the nominal position at isocentre decreased gamma 
pass-rates by 2% per mm shift. Superior/Inferior shifts from the nominal position at 
isocentre decreased gamma pass-rates by 13% per mm shift. 
 
ArcCheck analysis 
 
Gamma analysis (2%, 2mm criterion) was performed between the measured diode 
dose and the calculated diode dose for each plan. Average gamma pass rates for all 
three complexity levels are summarised in table 3.8. All ArcCheck results were within 
clinically acceptable limits. No significant differences in the gamma pass rates were 
observed between the three complexity levels. 
 
Table 3.8: Average ArcCheck gamma pass rates (2%, 2mm criterion) for C1, C2 and C3 plans. 
Wilcoxon matched-pair signed rank test (two tailed) p-values are listed for C1 vs. C2, C1 vs. C3 and 
C2 vs. C3 
 
Complexity level C1 C2 C3 C1/C2  
p 
C1/C3  
p 
C2/C3  
p 
Mean γ pass rate  ± 1S.D. 96% ± 4% 95% ± 3% 94% ± 5% 0.125 0.188 1.000 
 
3.3.6. Case study 
As a continuation of the case study presented in sections 3.1.3 and 3.2.3, case #1’s 
dose verification results are presented in this section to illustrate the typical dose 
verification results for C1, C2 and C3 plans.  
Time resolved point dose results for the PTV measurement points are displayed in 
figure 3.14. Integral point dose deviations for C1, C2 and C3 plans were 0.5%, -0.5% 
and 0.4% respectively. Dose deviations are visible for various control points for all 
complexity levels but the magnitude or frequency of these deviations do not increase 
with complexity. These deviations primarily originated from measurements made in 
the beam penumbra (section 3.3.3 : segment dose analysis). 
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.  
Figure 3.14: Time resolved point dose results (PTV measurement point) for case #1’s C1, C2 and C3 
plans. Integral point dose deviations for C1, C2 and C3 plans were 0.5%, -0.5% and 0.4% respectively. 
The deviations between measured and calculated dose primarily originated from measurements made 
in the beam penumbra. 
 
Film gamma maps for the PTV plane of the C1, C2 and C3 plans are displayed in 
figure 3.15. Film gamma pass rates (2%, 2mm) for C1, C2 and C3 plans were 95%, 
96% and 98% respectively.  
ArcCheck gamma maps for C1, C2 and C3 plans are displayed in figure 3.16.  
ArcCheck gamma pass rates (2%, 2 mm) for C1, C2 and C3 plans were 99%, 96% 
and 96% respectively. Overall, no clear differences in dosimetric accuracy were 
observed between the three complexity levels for case #1. 
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Figure 3.15: Film gamma maps (PTV planes) for case #1’s C1, C2 and C3 plans. Film gamma pass 
rates (2%, 2mm) for C1, C2 and C3 plans were 95%, 96% and 98% respectively. Gamma values are 
indicated with the colour scale from white to blue to red. Gamma maps were generated using 2%, 2mm 
criterion.  
 
 
 
Figure 3.16: ArcCheck gamma maps for case #1’s C1, C2 and C3 plans. ArcCheck gamma pass rates 
(2%, 2mm) for C1, C2 and C3 plans were 99%, 96% and 96% respectively. Red dots represent diodes 
failing gamma analysis with a high dose and blue dots represent diodes failing gamma analysis with a 
low dose.  Gamma maps were generated using 2%, 2mm criterion. 
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4. Discussion 
Ultimately, the motivation for exploring complex VMAT beam arrangements is to 
improve the quality of H&N RT treatment. Two major components of the overall 
quality of the treatment were investigated in this thesis: plan quality and plan 
dosimetric accuracy. Possible relationships between the two components and plan 
complexity were investigated by creating VMAT plans defined by a complexity level 
system, quantifying the complexity of those plans with metrics and performing dose 
verification measurements using three independent methods. Plan complexity is 
related to the fundamental parameters of VMAT plans such as the MLC motion, field 
size, dose rate modulation and gantry speed modulation. Plan complexity can be 
increased as a result of improving plan quality during optimisation. Additionally, plan 
complexity can also be related to the patient’s anatomy and the geometry of planning 
volumes. While higher complexity plans provide an opportunity to improve the 
quality of H&N RT treatment, they may also deteriorate the accuracy of VMAT 
delivery and TPS modelling. Whether this happens or not depends on several factors 
including the characteristics of the LINAC and the performance of the TPS dose 
calculation algorithm. Furthermore, the characteristics of the applied dose verification 
methods determine whether specific dosimetric deviations and therefore changes in 
dosimetric accuracy can be detected. Each of these aspects will be discussed in this 
chapter. 
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4.1. Plan Quality 
In this section, the plan quality characteristics produced by C1, C2 and C3 plans will 
be discussed in relation to the potential clinical impact they may have. The advantages 
and limitations of the planning methods used in this thesis will also be discussed.  
 
The objective of VMAT is to fully cover the target volumes with the prescribed dose 
while limiting the dose delivered to critical OARs that are not the target of the 
therapy. Failing to adequately spare OARs may result in toxicity to sensitive organs, 
potentially lowering the patient’s quality of life.  Equally important, the target 
volumes must be covered with the prescribed dose to ensure that the effectiveness of 
the therapy is not compromised. Plan quality is therefore measured in terms of the 
ability of a VMAT plan to achieve both of these aspects simultaneously.  In order to 
study the relationship between plan quality and plan complexity, plans categorised by 
three complexity levels were generated for five H&N cancer cases. It was found that 
by tightening the planning objectives, the dose delivered to the prioritised OARs 
(spinal cord, brain stem and parotid glands) could be dramatically decreased as 
indicated by the DVH metrics (section 3.1.2). While C2 and C3 plans were able to 
effectively decrease OAR doses, target coverage was not compromised and, in fact, 
improvements were made to the PTV66 D98 and PTV54 D50 on average (section 
3.1.1.). Additionally, the delivered dose to the non-prioritised OARs (oral cavity, 
mandible, larynx and pharynx) was not increased as a consequence of the focused 
sparing of the prioritised OARs (section 3.1.2).  
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Statistical significance 
The statistical significance of plan quality differences observed between the three 
complexity levels could not be proven for the sample size used in this study. 
However, some of the plan quality trends with complexity level were large in 
magnitude and consistently observed for all cases. It is estimated that statistical 
significance can be proven for the larger trends with the addition of three more cases 
that display similar results to the five cases presented in this thesis. 
4.1.1 Spinal cord dose 
Relative to C1 plans, C2 and C3 plans produced steeper dose drop off along the 
posterior/inferior axis (figures 3.2, 3.4), reducing the D1cc to the SCPRV (tables 3.2, 
3.3). The SC dose reduction achieved by the C2 and C3 plans would not likely reduce 
the NTCP for myelopathy [62] as the C1 plans were already achieving sufficiently 
low doses resulting in a negligible NTCP. However, reducing the planned SC dose 
during the first course of radiotherapy may be beneficial for possible future re-
treatment. This is because the previously accumulated SC dose may often be the 
limiting factor for the target volume prescription of the re-treatment. More 
importantly for patient positioning, the minimum distance from the SCPRV to the 50 
Gy isodose was increased with the C2 and C3 plans (tables 3.2, figure 3.3). With day 
to day patient positioning setup variation including patient deformation, the SC may 
be moved into a 50 Gy dose region. Where the SC is at risk due to the proximity to 
high dose areas, the clinical instruction is to position the patient with focus on 
positioning the SC in the correct position. However, this compromise in patient 
positioning can result in an under-dosage of the target volume(s). By creating a larger 
distance between the SC and the 50 Gy isodose, the impact of this kind of 
compromise can be reduced or avoided completely.  
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4.1.2. Brain stem dose 
For cases where the brain stem was close to the target volumes, C2 and C3 plans were 
able to greatly reduce the BS D1 relative to the C1 plans (tables 3.2, 3.3). Discussion 
of the brain stem dose is similar to the spinal cord. The dose reductions achieved by 
the C2 and C3 plans would not likely reduce the NTCP for brain stem injury [63] 
because the C1 plans were already achieving sufficiently low doses resulting in 
negligible NTCP. However, reducing the planned BS dose during the first course of 
radiotherapy may be beneficial for possible future re-treatment. Additionally with 
reduced dose, the critical 54 Gy isodose is more likely to be positioned further away 
from the BS.  
4.1.3. Parotid gland dose 
Relative to C1 plans, C2 and C3 plans reduced the mean dose delivered to the parotid 
glands (tables 3.2, 3.3). Large mean dose reductions of 6 to 8 Gy were achievable by 
C3 plans where the corresponding C1 plan produced mean doses above 20 Gy. 
Smaller dose reductions of 2 to 4 Gy were obtained by C3 plans where the 
corresponding C1 plan produced mean doses below 15 Gy. Several groups have 
investigated the NTCP dose response for parotid gland xerostomia [64, 65, 66].Their 
work suggests that the incidence of xerostomia can be significantly decreased if the 
mean dose delivered to at least one parotid gland is kept below 26 Gy. Additionally, 
further dose reductions below 26 Gy also imply decreased xerostomia NTCP. 
Therefore, all parotid gland dose reductions achieved by C2 and C3 plans may be 
expected to improve post radiotherapy salivary function to some extent. Further, there 
is likely heterogeneity between individual’s dose responses due to genetic make-up, 
whether the patient also has adjuvant/concurrent chemotherapy and other factors. 
Additionally, uncertainty in the NTCP models adds to the uncertainty of an individual 
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patient response. These are all further reasons to reduce parotid dose to the greatest 
feasible extent for each patient. 
4.1.4. Advantages and disadvantages of the complexity level system 
One of the motivating factors behind this study was to determine whether the plan 
quality currently delivered clinically at the WBCC could be improved upon. For this 
reason, it was necessary to compare newly generated VMAT plans to the clinical 
plans. The three tier complexity level system used to generate the plans allowed for 
plan quality improvements to be studied for individual patients. This was important as 
the purpose for creating further plans remained clinically relevant (i.e. decreasing 
NTCP for individual patients). Furthermore, by creating multiple plans for individual 
patients, the effect of plan complexity on the quality of the plan could be identified 
without the added variability due to differences in patient anatomy and the definition 
of planning volumes. A disadvantage of the planning approach was that the long time 
required to generate new plans essentially limited the number of cases that were able 
to be studied within the allocated time frame. Additionally, the method used to 
generate C3 plans did not allow for true pareto-optimal plans to be found. With more 
time, multiple plans with varied sparing of each individual OAR could have been 
created so the trade-offs of sparing different OARs could be observed. By more fully 
exploring the trade-offs, it could have been stated with greater certainty that a given 
C3 plan was pareto-optimal. 
4.2. Plan complexity 
In this section each aspect of plan complexity studied in this thesis will be related to 
the possible impact they may have on the dosimetric accuracy of the TPS dose 
calculation and delivery on the LINAC. Additionally, the relationships between the 
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three calculated complexity metrics and the plan MU will be discussed as a potential 
tool to be used during optimisation. The limitations of the complexity level planning 
system used to generate the plans will be discussed.  
 
Plan MU was increased when optimisation constraints were tightened to improve plan 
quality (section 3.2.1). If plan quality is related to plan complexity then the plan MU 
seems to give some indication of complexity. However, the plan MU by itself does 
not directly provide information about the plan’s fundamental VMAT parameters 
such as MLC motion, field size, dose rate and gantry speed. Furthermore, the three 
complexity levels served only as a qualitative complexity measure, but continuous 
quantitative complexity measures would be required to eventually relate plan 
complexity with plan dosimetric accuracy. Therefore, complexity metrics were 
calculated to quantify plan complexity in relation to the plan parameters. 
Additionally, each plan’s gantry rotation speed and dose rate delivery were 
characterised by plotting both for all segments for each beam. 
 
Statistical significance 
The statistical significance of the differences observed in plan complexity between the 
three complexity levels could not be proven for the sample size used in this study. 
However, some of the complexity metrics trends with complexity level were large in 
magnitude and consistently observed for all cases. It is estimated that statistical 
significance can be proven for the larger trends with three more cases that display 
similar results to the five cases presented in this thesis. 
4.2.1 MU & Gantry speed 
The results (figure 3.5) show that for the five cases in this study, improvements to 
plan quality made with C2 and C3 plans also consistently increased the MU utilised 
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by the plans. This result generally agrees with a previous study that looked at the 
trade-offs between achievable plan quality and required plan MU for static gantry 
IMRT [38]. A consequence of high total plan MU was that the MU delivered for each 
segment was also high. This meant that on average, the C2 and C3 plans required 
higher dose rates than the C1 plans during delivery on the LINAC. However, none of 
the segments in any of the plans required delivered dose rates that were greater than 
the maximum LINAC limit of 600 MU/min. Therefore, gantry speed modulation was 
not required to deliver the planned MU weight for any of the segments of any of the 
plans. The advantage of not requiring gantry speed modulation was that the treatment 
delivery time was identical for all plans. Additionally, delivery error potentially 
arising from modulating the speed of the heavy LINAC head was avoided.  
4.2.2. Field size 
For the five cases in this study, the results (figure 3.5) show that improvements to 
plan quality made with C2 and C3 plans required the use of smaller MLC defined 
field sizes. The ALPO metric showed that leaf pair openings were on smaller on 
average for C2 and C3 plans. More importantly, C2 and C3 plans used a higher 
proportion of leaf pair openings less than 1.0 cm in size indicated by the CLPO 
metric. This is important for the accuracy of TPS dose calculation because it has 
previously been shown that the largest dose calculation errors using AAA occur for 
MLC defined field sizes that are smaller than 1.0x1.0 cm. Kron et al. [67] showed that 
for 1.0x1.0 cm fields, the AAA algorithm could under predict the delivered dose by 
anywhere from ~1% to ~7% depending on the selection of MLC transmission, 
dosimetric leaf gap and focal spot beam model parameters. The WBCC TrueBeam 
LINAC beam model has not yet been optimised for the calculation of small fields. 
Therefore, it is likely that for segments containing field sizes 1.0x1.0 cm or less there 
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are systematic errors ranging from ~1% to ~7% introduced into the AAA dose 
calculation. Improvements to the WBCC beam model for small fields could be made 
by adjusting the beam model parameters to more closely match the dose calculation to 
measurements made with a high spatial resolution detector. 
4.2.3. Leaf travel 
For the five cases in this study, the results (figure 3.5) show that the C2 and C3 plans 
on average had higher LT than the corresponding C1 plans. For the same gantry 
rotation speed, higher LT implies higher leaf speeds on average during delivery. It has 
been previously reported that the magnitude of random dynamic MLC position errors 
can increase with leaf speed [68]. Data from LINAC delivery log files showed that the 
maximal MLC leaf positioning error was less than 0.6 mm for all C1, C2 and C3 
plans regardless of the differences in LT between complexity levels.  As the 
magnitude of random MLC positioning errors were similar for all complexity levels, 
it is likely that the dosimetric impact of random MLC errors was also similar for all 
complexity levels. Regardless, it has previously been shown that random MLC 
position errors of up to 1.2 mm have negligible impact on the dose distribution [69].  
Masi et al. previously showed that increased LT can correlate with poor dose 
verification results for plans calculated with 4º control point spacing [70]. However, 
the strength of the observed correlation was reduced when they recalculated the plans 
with a higher resolution 2º/3º control point spacing. In the RapidArc implementation 
of VMAT, plans are calculated with a control point spacing of approximately 2º, 
therefore the dose calculation inaccuracies observed by Masi et al. were unlikely to be 
replicated by the WBCC VMAT setup.  
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4.2.4. Complexity variation with case 
Within a complexity level, all complexity metrics displayed considerable variation 
from case to case (figure 3.5). The variation possibly indicates that the complexity of 
a plan is related to the patient’s anatomy and the geometry of the planning volumes. 
This demonstrates that using a MU constraint may not be ideal because some patients 
may require increased plan complexity to achieve the same level of plan quality as 
other patients.  Plan complexity variation for different anatomy and planning volume 
geometry was similarly demonstrated for static gantry IMRT by McNiven et al. [36] 
where large variation in utilised MU and their calculated complexity metric was 
reported for various treatment sites. Plan complexity variation was also likely caused 
by the limitations of the complexity level planning system which is further explained 
in section 4.2.8. 
4.2.5. Differences in complexity between CCW & CW beams 
Differences were observed in the complexity metrics between the CCW and CW 
beams. CW beams were generally more complex than the corresponding CCW beam 
(fig 3.6). This may indicate that each beam delivers dose in different ways. For 
example, for one case it was observed that the CCW beam was more conformal 
covering just the PTV while the CW was more modulated completing the PTV dose 
delivery. In another case, one beam mostly delivered dose to one half of the PTV66 
while the second beam covered the remaining half. It is currently uncertain how the 
complexity of each beam is determined and more work is required to further 
understand these observations.  
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4.2.6. Relationships between ALPO/CLPO/LT and MU 
Complexity metrics have previously been related to the degradation of the agreement 
between TPS calculated dose and dose measured with QA verification methods [36, 
70, 71]. Hypothetically, if the dosimetric agreement between calculated and measured 
dose was found to degrade with increased plan complexity, it would be beneficial to 
relate poor dose verification results with one or more particular treatment plan 
parameters quantified by complexity metrics. With knowledge of what plan 
parameters result in degradation of deliverability, steps could be taken to ensure that 
plans with those kinds of complexities are avoided during optimisation. Ideally, the 
important complexity metrics would be available to the planner in real time so the 
plan complexity could be effectively monitored and controlled during optimisation. 
However, with the current version of the optimiser (PRO version 11.0.31), only the 
MU used by the current iteration of the plan is available to the planner. Therefore, for 
the current version of the optimiser, plan complexity can only be inferred from the 
reported plan MU. Trends were observed between the three calculated metrics 
(ALPO, CLPO, LT) and plan MU, but none were strongly correlated (fig 3.7-3.9). As 
none of the correlations were strong, the application of such correlations to control 
plan complexity during optimisation is limited. However, in the case of the WBCC 
VMAT system, no degradation of dosimetric accuracy with increased plan complexity 
was observed for the five cases in this study (section 3.3). Therefore, it appears that an 
upper limit on plan complexity is not required to ensure dosimetric accuracy for the 
WBCC VMAT system. This will be discussed in more detail in section 4.3. 
4.2.7. TPS version 11 upgrade 
The eclipse TPS was unavoidably upgraded from version 10.0.28 to 10.0.31 half way 
through this study.  As such, the impact of the eclipse v11 upgrade on plan 
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complexity was assessed (section 3.2.4). It was important to assess how the upgrade 
had changed the VMAT optimiser because all C1 plans were generated with the old 
v10 optimiser while the majority of C2 and C3 plans were generated with the v11 
optimiser. Differences between the optimiser versions may have changed the 
complexity of the plans irrespective of plan quality. This would potentially increase 
the uncertainty of the observed trends between the complexity metrics and complexity 
level (figure 3.5). The primary difference between optimiser versions was observed 
for the LT metric where the v11 optimiser sometimes would generate plans with 
higher LT. However, changes in LT were also observed with re-optimisations of v10 
plans using the same v10 optimiser. Therefore, it is not possible to attribute this 
change to the optimiser version alone because the process of re-optimisation also 
changes the LT. However, as a result, there may be increased uncertainty surrounding 
the change in LT from C1 to C2 plans. The only consistently observed difference 
between optimisation versions was that the v11 plans had more discrete changes in 
dose rate as compared to the continuous dose rate changes exhibited by v10 plans 
(figure 3.10). However, it is not likely that this difference in planned dose rate would 
have changed the accuracy of dose delivery by the LINAC. Differences between 
optimiser versions for ALPO, CLPO and MU were negligible and would not likely 
influence the observed trends between complexity levels. 
4.2.8. Limitations of the complexity level planning system 
The complexity level planning system allowed for a range of plan complexity to be 
generated and related with plan quality. However, the system also created overlap in 
the complexity metrics between the complexity levels. For example, the highest 
complexity C1 plans were more complex than the lowest complexity C2 plans in 
terms of the complexity metrics. The overlap was partially a result of the variability in 
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plan complexity for different patient anatomy and planning volume geometry, but also 
partially due to the complexity level system itself. The primary limitation of the 
system was that it assumed that the C3 plans were pareto-optimal. As the quality of 
the C2 plans were defined to be half way between the C1 and C3 plans, it was 
important that the C3 plans were generated in a consistent way. By not adequately 
controlling the plan quality in a consistent way for each case, plan complexity 
variability may have been increased within each complexity level.  
4.2.9. Other considerations 
A potential downside to increased MU utilisation with higher complexity plans is that 
the patient can be exposed to higher out of field dose. A study by Hall, looking at the 
differences between 3DCRT and IMRT has suggested that increased to out of field 
patient exposure due to LINAC head leakage and MLC transmission radiation are 
factors that may increase the probability of inducing secondary cancers [27]. Hall 
concluded that IMRT may double the probability of induced secondary cancers 
relative to 3DCRT (1.5 % to 3.0 % 10 years after radiotherapy). In this study, relative 
to the C1 plans, C3 plans increased plan MU by 55% on average. An increase in plan 
MU will increase the out of field dose from radiation transmitted through the MLC 
leaves. However, the C3 plans would not increase patient exposure to leakage 
radiation from the LINAC head because the delivery times for all complexity plans 
were identical (4.2.1.). The differences between 3DCRT and IMRT delivery times 
and MU usage considered by Hall are much greater than differences between high and 
low complexity plans in this study. Therefore, the probability of inducing secondary 
cancer with higher complexity VMAT plans is not likely to be much different than 
with lower complexity VMAT plans. Even so, this should be kept under consideration 
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and steps to reduce transmission through the MLC and leakage from the LINAC head 
should be taken where possible to minimise the patient’s out of field exposure.  
4.3. Plan dosimetry verification 
In this section, the results of the dose verification measurements will be discussed and 
the strengths and weaknesses of each verification method will be highlighted. The 
results of the dose verification methods will also be discussed in relation to plan 
complexity and plan quality.  
 
The overall accuracy of VMAT treatment depends on multiple factors including 
patient positioning, accuracy of the TPS dose calculation and the accuracy of dose 
delivery by the LINAC. In this project I have studied the agreement between the TPS 
calculated dose and LINAC delivered dose (dosimetric accuracy) for a variety of plan 
complexity. Dosimetric accuracy is important because planning decisions are made 
using the calculated dose and for the most part, the calculated dose is expected to be 
reproduced in reality. With increased plan complexity, certain plan parameters may 
degrade the accuracy of the dose calculation and/or the dose delivery. For this reason, 
end-to-end dose verification measurements were performed to assess the dosimetric 
accuracy for C1, C2 and C3 plans. The verification results were averaged for each 
complexity level to identify whether dosimetric accuracy was changed with plan 
complexity. Three independent verification methods were used to form a more 
complete picture of dosimetric accuracy. Each method has its strengths and weakness 
and only by considering the results of all three methods together can the question of a 
plan’s dosimetric accuracy be answered with confidence.  
76 
 
4.3.1. LINAC dose delivery repeatability 
The Truebeam LINAC at the WBCC was able to deliver integral dose to a small 
volume with repeatability better than 0.1% for both C1 and C3 plans (table 3.5). 
Additionally, segment dose delivery repeatability was better than 0.6% for both C1 
and C3 plans (table 3.5).  These results suggest that the increased plan complexity of 
the C3 plan did not negatively impact on the repeatability of the dose delivery. It is 
noteworthy that the stated repeatability figures also include uncertainty of the 
measurement process including Ktp correction of each run and leakage correction.  
The advantage of using time resolved point dose measurements was that the dose 
delivery could be assessed for all segments rather than just the integral dose. 
Additionally, the point dose method gave adequately stable measurements so the 
repeatability of the LINAC dose delivery itself was resolved. This type of analysis 
gave confidence that the measured integral dose was not a result of large random 
errors cancelling out. Rather, the dose delivery at every segment was found to be 
highly repeatable, resulting in a highly repeatable integral dose delivery (fig 3.11 & 
3.12). The high repeatability of segment dose delivery may indicate that the LINAC 
was operating within its limitations for both high and low plan complexity plans. 
 
A disadvantage of the point dose method was that the repeatability was only assessed 
at one small volume in the phantom. It is possible that the dose delivery repeatability 
was different in other locations and missed by this experiment. Film or ArcCheck also 
could have been used for this experiment, but the uncertainties associated with these 
two methods were too large and LINAC dose delivery repeatability would not be 
resolved beneath the uncertainty of the measurement method itself.  
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4.3.2. Impact of dose grid resolution 
Reducing the dose grid resolution from 1.5 mm to 1.0 mm was found to decrease the 
calculated volume doses by around 1 % (section 3.3.2). The calculated dose was 
reduced by slightly more for C3 plans than for C1 plans indicating that this effect may 
be larger for more highly modulated beams. A 1.0 mm dose grid resolution was 
selected for dose verification analysis as it provided the most accurate dose 
calculation. This has similarly been observed by Ong et al. [40] for AAA v10, where 
it was recommended that a 1.0 mm dose grid resolution should be used for higher 
complexity plans due to dose calculation inaccuracies when calculating with lower 
dose grid resolutions. Additionally, Ong et al. reported that the dosimetric 
inaccuracies with were larger in low density media. Therefore for high complexity 
plans, it is recommended that a 1.0 mm dose grid resolution is also used for the dose 
calculation on the patient’s anatomy to maximise the dosimetric accuracy for the 
assessment of plan quality.  A practical downside to calculating at a 1.0 mm dose grid 
resolution was that calculation times were doubled to 60-90 minutes compared to 45 
minutes with a 1.5 mm dose grid resolution due to the increased computational 
overhead. This issue may be resolved with the use of higher specification computer 
hardware and by porting the dose calculation from the central processing unit to the 
graphics processing unit [72]. 
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4.3.3. Point dose verification 
Segment point dose analysis 
 
Analysis of the dose deviation per segment as described by Louwe et al. [48] did not 
reveal significant systematic differences between the three complexity levels. 
The only deviations that were observed above the background noise level were for 
segments where the detector was located near the beam penumbra (figure 3.13). For 
our department, the origin and magnitude of these deviations have been well 
characterised [48]. Louwe et al. found that these deviations were primarily caused by 
inaccuracies in the modelling of the beam penumbra. This project’s data set was too 
small to make further analysis of these deviations meaningful. Previous experience 
within the department showed that at least 50-100 time-resolved point dose 
measurements are required to resolve the smallest systematic deviations from the 
random noise resulting from inaccuracies in detector positioning. 
 
Integral point dose analysis 
No significant trends were observed in the integral point dose deviations between the 
three complexity levels. Additionally, averaged point dose deviations for all three 
complexity levels were very close to 0.0% (table 3.6) suggesting that for the five 
cases in this study there were no large systematic differences between the delivered 
and calculated doses for any of the complexity levels. 
From the three methods used in this study, the point dose method provided the most 
accurate measurement of absolute dose. This is because for VMAT dose 
measurement, the characteristics of the pinpoint ionisation chambers were well 
understood and the dose calibration factor was traceable back to the Australasian 
primary standard (Australian Radiation Protection and Nuclear Safety Agency, 
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ARPANSA). However, individual point dose measurements were very sensitive to 
detector positioning where the sensitivity was mostly dependent on the steepness of 
dose gradients surrounding the detector. The effect of this can be seen in the results 
where the measurement variability for OAR points measured on steep dose gradients 
was higher than for PTV points measured on relatively shallow dose gradients. 
Additionally, the measurement uncertainty for OAR points was higher for C2 and C3 
plans than for C1 plans (table 3.6) possibly as a result of the steeper dose gradients 
generated by higher complexity plans. Where possible, measurement points were 
selected on relatively shallow dose gradients to minimise the measurement’s 
sensitivity to detector positioning. Additionally, multiple points located at the same 
position were measured sequentially without moving the phantom to reduce 
measurement variation introduced from resetting the phantom. 
Dose gradients also had an effect on the chamber measurement itself through volume 
averaging [53, 54]. As the differences in dosimetric accuracy between complexity 
levels may have been very small it was important to minimise uncertainty in the 
analysis method where possible.  The active volume of the chamber was 5 mm long 
on the longitudinal axis of the chamber (table 2.5). As a result, dose gradients along 
this axis of the chamber introduced noticeable volume averaging into the 
measurements. Initially, a single voxel was used to extract the TPS calculated dose at 
each measurement point. However, it was found with dose gradients crossing the 
measurement point, the selection of the voxel had a large impact on the calculation of 
the dose deviation. It was realised that the measurement of dose with the pinpoint 
chamber was made in a small volume. Therefore, to account for volume averaging, 
the calculated point dose was taken as the mean dose delivered to voxels contained 
inside a contour drawn with the same dimensions as the chamber’s active volume. 
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Essentially this selection of the calculated dose modelled how the chamber was 
actually measuring dose and the uncertainty of the point dose deviation calculation 
was reduced because a single voxel was no longer used as the comparison dose. This 
method was selected over gamma analysis so dose deviations could be averaged for 
each complexity level.  
4.3.4. Film dose verification 
For the five cases in this study, no significant trends were observed in the film gamma 
pass-rates and mean gamma values between the three complexity levels (table 
3.7).The results indicate that the higher complexity plans did not significantly degrade 
dosimetric accuracy for the coronal dose planes selected in the PTV and OAR 
regions. Additionally, qualitative analysis using dose profiles showed that the 
expected plan quality improvements observed with the TPS calculated dose were 
accurately replicated with LINAC delivery.  
Film measurements extended dose measurements to coronal planes so the spatial 
accuracy of the delivered dose distribution could be verified in addition to the 
absolute dose of the delivered dose. The absolute dose produced by film was verified 
by selecting measurement planes that also contained point dose measurements. 
Absolute dose between film and point dose dosimetry agreed within 2% for all planes. 
It is important to note the comparison between film and point dose was made using 
single film voxel doses rather than a volume similar to the method explained in 
section 2.3.1. Small dose deviations existed at various locations on all films but did 
not appear to increase in frequency or magnitude with increased plan complexity 
(figure 3.15). The overall dosimetric accuracy of each film plane was quantified with 
gamma analysis. For gamma analysis, the ΔD =2% criterion was selected to be 
consistent with point dose analysis where absolute dose deviations of up to 2% was 
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within clinically acceptable levels. DTA = 2 mm was selected because generally a 
positional deviation of up to 2 mm was also considered clinically acceptable. 
However, for plans where the 50 Gy isodose was within 2 mm of the SC or BS, this 
DTA criterion may have been too lenient because a positional deviation of 1 mm to 2 
mm of the 50 Gy isodose near the SC/BS would be considered important.  
4.3.5. ArcCheck dose verification 
For the five cases in this study, no significant trends were observed in the ArcCheck 
gamma pass-rates between the three complexity levels (table 3.8). The results indicate 
that the higher complexity plans did not significantly degrade dosimetric accuracy. 
The ArcCheck phantom enables analysis of VMAT dosimetric accuracy through 
measurement of the entrance and exit dose with diodes spaced around the cylindrical 
phantom.  The integral measured dose is a sum of all entrance and exit dose 
contributions from each delivered segment. Gamma analysis comparison is performed 
between the integral dose measured by each diode and the TPS calculated dose. The 
ArcCheck is a practical method to quickly perform dose verification of the entire dose 
delivery. Additionally, the ArcCheck provides a test of the TPS dose calculation 
accuracy for a phantom material other than water (PMMA) which may be important 
for the dose calculation on the patient anatomy because structures of various densities 
exist in the H&N. However due to the ArcCheck’s poor spatial resolution between 
diodes (1.0 cm spacing), its utility to detect differences in the dosimetric accuracy 
between complexity levels was limited to large dosimetric deviations. In this sense, 
the ArcCheck has provided data that shows that there is no large degradation of the 
dosimetric accuracy for higher complexity plans but cannot resolve smaller 
differences between complexity levels that may also exist. This lack of sensitivity to 
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dosimetric deviations has also been demonstrated for other commonly used detector 
array QC phantoms [73].   
4.3.6. VMAT insensitivity to errors 
Three independent dose verification methods have indicated that dosimetric accuracy 
was not degraded with increased plan complexity. This result initially seems 
counterintuitive given that large systematic dosimetric deviations originating from 
inaccuracies in AAA were expected to exist for segments containing LPOs smaller 
than 1.0x1.0 cm as discussed in section 4.2.2. Additionally, other systematic 
deviations may also exist that have not yet been identified. Because these deviations 
have not had a large effect on the integral dose, it is implied that for VMAT, the 
integral dose may be insensitive to certain types of dosimetric deviations. This 
insensitivity may be because the systematic segment deviations become diluted due to 
geometry of VMAT delivery itself. For example, consider a systematic deviation 
between the LINAC delivered and TPS calculated dose resulting from the inadequate 
TPS modelling of the MLC inter-leaf leakage. In this scenario, the voxels that are 
irradiated with inter-leaf leakage during delivery will accumulate systematic 
deviations. For a collimator rotation of 0 degrees, voxels remain stationary in the 
beam’s eye view during gantry rotation and the same voxels are always irradiated 
with inter-leaf leakage. Therefore, the systematic deviations from each of the 
segments add up in the integral dose. However for a rotated collimator angle, voxels 
rotate in ellipses in the beam’s eye view during gantry rotation. Therefore, for a 
rotated collimator angle many different voxels are exposed to inter-leaf leakage 
radiation and the systematic deviations from each segment no longer adds up to 
become significant in the integral dose. With this kind of mechanism, the segment 
systematic deviations can be averaged out of the integral dose.  
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A similar argument can be applied to the systematic deviations originating from the 
TPS calculation of small fields. In this case, the systematic deviations only become 
large for fields below a certain threshold size, so these deviations are transient in 
nature. Further, small fields can be located in many locations in the beams eye view 
and affect many different regions of voxels. Finally, as described previously, the 
collimator rotation results in voxels moving in ellipses in the beam’s eye view as the 
gantry is rotated. As such, the systematic deviations arising from small fields would 
not have the opportunity to add up for any particular group of voxels during the 
delivery of the arc. The remaining fluence delivered through large fields is correctly 
calculated by AAA and do not contribute large systematic deviations. For plans with a 
combination of large and small fields, the systematic deviations arising from small 
fields make up a negligible contribution to the overall delivered fluence. This effect 
would not hold for regions of voxels that acquire the majority of their dose from 
fluence delivered through small fields.  
VMAT’s insensitivity to various systematic and random delivery errors has also been 
demonstrated by Betzel et al. [74]. 
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5. Conclusion 
VMAT is the latest technological advance in LINAC based radiotherapy that 
improves the quality of treatment plans used to treat H&N cancer patients. While the 
VMAT delivery modality itself has improved the quality of H&N treatment plans, 
further steps can be taken to ensure that the highest quality treatment plans are 
generated for each patient. This study has shown that the quality of a given VMAT 
plan is highly dependent on how far a plan is pushed towards a pareto-optimal 
solution during optimisation. It has been demonstrated that the quality of VMAT 
plans can be improved upon by not using a MU objective that restricts plan 
complexity and by aggressively applying DVOs to planning volumes during 
optimisation. For five cases, higher complexity plans have been generated that 
improve plan quality beyond what is achievable with the planning protocol currently 
used in WBCC clinical practice. Characteristics of plan complexity have been 
quantified with metrics and show that higher complexity plans on average utilise 
smaller field sizes, higher leaf travel and higher monitor units. The results from three 
independent dose verification methods have indicated that dosimetric accuracy was 
not degraded by the higher complexity plans compared to the clinical WBCC plans. 
These results give confidence that VMAT plans more complex than those currently 
used clinically at the WBCC can be accurately calculated and delivered within 
clinically acceptable limits. H&N VMAT at the WBCC can now be developed further 
with greater confidence in the dosimetric accuracy of higher complexity plans. 
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